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Abstract
Osteoarthritis (OA), is a chronic debilitating disease that affects millions of individuals and is
characterized by the degeneration of joint subchondral bone and cartilage. These tissue
degenerations manifest as joint pain, limited range of joint motion, and overall diminished
quality of life. Currently, the exact mechanism(s) and cause(s) by which OA initiates and
progresses remain unknown. The multi-factorial complex nature of OA (i.e. age, diabetes,
obesity, and prior injuries have all been shown to play a role in OA) contributes to the current
lack of a cure or effective long-term treatment for OA.
One re-emerging and interesting hypothesis revolves around the delicate homeostatic
microvascular environment around the cartilage – an avascular tissue. The absence of blood
vessels within cartilage stresses the importance of nutrient and oxygen delivery from the
neighbouring synovium and subchondral bone. Currently, the effects of changes in the
subchondral bone microvessel density on cartilage health remain unknown due to the
difficulties in simultaneously studying dense bone and the associated small microvessels.
Computed tomography (CT) is widely used in the diagnosis of OA, as the use of x-rays
provide detailed images of the bone degeneration associated with OA. However, the study of
microvessels using CT has been exceptionally difficult due to their small (< 10 µm) size, lack
of contrast from neighbouring soft tissues, and proximity to dense bone. The purpose of this
thesis was to develop a novel dual-energy micro-computed tomography (DECT) compatible
vascular perfusion contrast agent and the associated instrumentation to optimize DECT on
pre-clinical, cone-beam micro-CT scanners. The combination of these two techniques would
facilitate the simultaneous visualization and quantification of subchondral bone and
microvessels within the bone underlining the cartilage (i.e. distal femoral epiphysis and
proximal tibial epiphysis) of rats that have undergone an OA-induced surgery. Results gained
from this study will further provide information into the role that microvessels may play in
OA.
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Chapter 1
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INTRODUCTION

1.1 The Importance of Microvessels
The health and maintenance of the humans’ body vascular supply is essential for the
well-being of every single tissue and organ. The vast blood vessel network, specifically
the microvessels (i.e. capillaries, < 10 µm) are responsible for the transportation of
oxygen, nutrients, and inflammatory molecules to tissues, as well as the removal of CO2
and waste products.1,2 Thus, adverse changes to the vascular supply (i.e. reduced blood
flow or increased inflammatory response) may affect local tissues before cascading into
larger and more detrimental effects on the body.
Alterations to the blood circulatory system have been linked to a variety of diseases:
diabetes,3 avascular necrosis,4 cancer,5-7 osteoporosis,8-10 and osteoarthritis.11,12 Among
these diseases, osteoarthritis – a chronic degenerative joint disease that affects both the
growing and aging populations – is noteworthy. Despite the connection between
microvessels and osteoarthritis, the administration of anti-angiogenic13 or possible
angiogenic drugs14 has yielded limited success. Presently, with no available cure and
limited treatment success, the concern among the affected populations is ever-increasing.
It is apparent that knowledge gaps surrounding the mechanisms by which changes in the
vascular supply may promote the development of osteoarthritis remain. Thus, research
into the role and mechanism(s) which microvessels play in the initiation and progression
of osteoarthritis may provide new insight and identify targets for treatments and
preventative measures.
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1.2 Osteoarthritis
Osteoarthritis (OA) is a chronic debilitating joint disease and is the most common form of
arthritis (i.e. rheumatoid, osteoarthritis, psoriatic, etc).16-19 Osteoarthritis affects millions
of individuals;20-23 in Canada alone, ~ 10% over the age of 15 are affected 24 and by 2030,
it is projected that a total of 25% (~9 million) of the Canadian population will have OA.25
Clinically, OA is diagnosed through the examination of x-ray images for the presence of
cartilage loss, joint space narrowing, bone degeneration and spurs on x-ray images
(Figure 1.1).26-29 This joint disease commonly affects the hand, hip, knee, back, and
neck.20,24,26,30,31 Symptomatically, OA manifests as painful and stiff joints, which limit
mobility and prevent the ability to perform simple tasks (i.e. sit-to-stand motion, fine
motor skills to hold utensils, etc.), resulting in an overall decrease in quality of life for
patients.32

Figure 1.1: Overview of the physiological effects of osteoarthritis on the knee joint. The right side
(medial) side of the figure demonstrates the bone and cartilage degeneration associated with OA,
while the left (lateral) side demonstrates a healthy knee joint. Reproduced with permission from
Felson et al., 2006.15 Copyright Massachusetts Medical Society.
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In addition to the physical burdens imposed by OA, the costs associated with its
management are extremely high. In Canada, the health care costs of OA are projected to
increase from $2.9 billion to $7.6 billion by 2031.33 The largest contributions (> 40%) to
health care costs are hospital inpatient costs, elective surgeries, and revision joint
replacement surgeries (Figure 1.2).34 The total cost of OA management is further
increased with the addition of work loss costs;35 in Canada, these costs alone
exceed $17.5 billion.33,35

Figure 1.2: Pie chart demonstrating the relative cost breakdown for individuals affected with
OA. Reproduced with permission from Hunter et al., 2014.34 Copyright Springer Nature.

The extensive physical and economic burden imposed by OA has provided the
motivation for research into developing treatments for OA. Unfortunately, there does not
yet exist an effective disease modifying osteoarthritis drug (DMOAD) that can reverse
the cartilage and bone degeneration caused by OA, with current prescribed medications
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alleviating only the OA-associated pain.36,37 At the moment, total joint replacements
(TJRs) are presented as the only effective long-term solution to OA.38,39 However, these
metal and plastic implants eventually fail due to poor bone integration, implant loosening,
wear, and stress shielding.33

40,41

Thus, TJRs are not a permanent solution and require a

replacement every 15 – 20 years.42-45 Replacing an implant requires revision surgeries,
which can increase the risk of complications (i.e. infections) and subsequently, costs to
the healthcare system and patient. The absence of a permanent solution to treat and
reverse the course of OA emphasizes the need for further research into understanding the
cause(s) and mechanism(s) of OA. Information garnered from these studies may result in
a better understanding of OA and lead to improvements of current methodologies, or
alternative targets for DMOADs, treatments, and preventative measures.

1.2.1

Microvascular Environment of Joints

In humans, the exact cause(s) by which OA is initiated remains unknown. However,
research has shown that individuals may be more susceptible to developing OA
depending on pre-existing injuries,46-48 age,49,50 gender,50,51 obesity,50,52,53 genetic predisposition,54,55 or diabetes.53,56,57 The wide variety of OA-associated factors (as listed
above) emphasizes the multifactorial nature of OA and the difficulty in formulating an
effective strategy for OA’s treatment and prevention.
A re-emerging hypothesis on the initiation of OA revolves around the microvascular
supply of the joint;12,58 where the previously mentioned factors may share a common
association through changes in vessel architectures and densities. The role of
microvessels in OA has been demonstrated through their ability to invade avascular
cartilage and release inflammatory factors that facilitate the degeneration and
calcification of cartilage.59
The microvessel hypothesis speculates that changes to the delicate homeostatic nature of
the microvessels results in subchondral bone changes that facilitate the vascular invasion
into cartilage (Figure 1.3, right).12,60 Responsible for nutrients, inflammatory response,
and waste removal (Figure 1.3, left), the microvascular environment is important for the
healthy maintenance of the joint. However, disturbances to the microvessel architecture
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and density may weaken the joint.12,61-65 It is not yet known whether the subchondral
bone changes, cartilaginous vascular invasion, and eventual OA are the result of a
decrease or increase in vascular density. Note that throughout this thesis, subchondral
bone will refer to the region of trabecular and cortical bone between physis and the
articular cartilage.

Figure 1.3: Diagram depicting healthy (left) and OA (right) subchondral bone and cartilage.
This figured shows the effect that vasculature and subchondral bone may have in the initiation
and progression of OA, leading to the degeneration of bone and cartilage observed with OA.
Reproduced with permission from Findlay et al.12 Copyright Oxford University Press.

Decreases in blood vessel density may lead to a diminished oxygen and nutrient flow to
the joint in conjunction with reduced waste removal.12,66-69 Combined these effects may
lead to the cartilage and bone degeneration observed within OA-affected joints.
Alternatively, an increase in vasculature may result in subchondral bone remodeling and
microvessel invasion into the cartilage. The subsequent release of inflammatory
molecules within the cartilage (normally an avascular tissue) triggers its self-
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degradation.70-73 With the renewed interest in vasculature becoming a target for OA
treatments, differentiating between increases and decreases of vascular density is required
for the proper administration of vessel suppressing or promoting drugs, respectively.
Therefore, studying the subtle vascular density changes within an animal model of OA is
crucial to understand the role of microvessels during the initiation and progression of OA.

1.2.2

Animal Models of Osteoarthritis

Animal research has been crucial in the study of how previously mentioned factors (i.e.
pre-existing injuries, age, obesity, etc.) play a role in OA.74-78 Results of animal studies
have led to the successful management of OA-induced symptoms within specific animal
models. Unfortunately, translation of treatments (derived from animal studies) to humans
has not shown the same level of success.79-84 The lack of an effective treatment may be
attributed to multiple factors: differences in the manifestation of OA between animals and
humans,85 genetic differences,86 differential joint loading,87 and possible yet-to-be
discovered factors. Regardless, animal models of OA are required to expand our
knowledge regarding the human pathogenesis of OA.
Induction of OA within animals can be achieved through naturally occurring,88,89
surgically-,74,90,91 or drug-induced models.77,92,93 While no current animal model perfectly
mimics the etiology of OA found in humans, each animal OA model reflects specific
portions of OA’s pathogenesis within humans.94
The anterior cruciate ligament transection (ACLX) and partial media meniscectomy
(PMM) surgically-induced animal model of OA95,96 is of interest. Within rats, the
combination of ACLX + PMM results in subchondral bone changes that closely resemble
the subchondral bone changes observed within early onset OA in humans.95 Therefore,
studying changes to the microvessel densities during the initiation and progression of this
surgically-induced animal model of OA may reveal whether an initial increase or
decrease in vascular density precedes or results from the observed subchondral bone
changes.
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1.2.2.1

Difficulties in Studying the Micro-Vasculature

Unfortunately, the visualization, characterization, and quantification of microvessels of
the joint is difficult due to multiple factors: (1) microvessels can be as small as 5-10 µm
(i.e. capillaries); (2) lack of inherent vascular contrast; and (3) their proximity to dense
tissues such as bone. Combined, these three challenges have proven difficult for any
single imaging technique.
The ideal imaging technique would be non-destructive (allowing for further sample
characterizations via other methodologies) and it would provide routine 3D visualization,
characterization and quantification of the microvascular environment and associated
skeletal structures in response to the surgical induction of OA (ACLX + PMM surgeries).
Information gained from such an imaging technique would provide insight into the role
of the microvasculature within subchondral bone during the initiation and progression of
OA.

1.3 Imaging Modalities for Micro-Vasculature and Bone
Analysis
Histology and light microscopy are considered the gold standard imaging techniques.5,97
Using a multitude of microscopic magnifications and stains, histology allows for the
visualization, characterization, and quantification of microvasculature.98,99 However, the
histological examination of bone is difficult due to bone’s highly compact mineralized
nature, which inhibits the blade from uniformly cutting through the sample. Thus,
samples containing bone are typically demineralized or decalcified prior to histologically
sectioning and staining. Due to the inherently destructive histological process, obtaining
3D representations of an entire sample requires laborious scanning and reconstruction of
serial sections.100-102 This process limits the applicability of histology with studies that
require high throughput (i.e. large numbers of specimens) or large samples (i.e. whole
limbs). However, pre-clinical imaging techniques such as micro-magnetic resonance
imaging, contrast-enhanced ultrasound, and micro-computed tomography can provide
images that would allow the visualization, characterization, and quantification of
microvessels and bone within in vitro and ex vivo intact specimens.
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Micro-magnetic resonance imaging (micro-MRI) is a non-destructive imaging technique
that can facilitate the visualization and characterization of microvessels and bones with
the use of various pulse sequences and contrast enhancements.103-105 Perfusion with
exogenous vascular contrast agents

106,107

allows for the detection of the contrast

enhanced vessels against the un-enhanced surrounding soft tissue. Micro-MRI possesses
the resolution necessary to detect in-plane microvessels (i.e. capillaries, < 10 µm).108
However, the image signal-to-noise (SNR) in combination with non-isotropic voxels,
hinders the accurate detection and characterization of microvessels within the large slice
thicknesses.109
Ultrasound (US) is a common and relatively inexpensive imaging technique, in
comparison to micro-MRI and micro-computed tomography.110 The use of contrastenhanced ultrasound (CEUS) is commonly employed to detect microvessels. Separately,
CEUS detects contrast-enhanced vessels facilitated with a bolus injection of microbubble
backscatters,5 and US can detect fractures along the bone surfaces.111,112 However, the
imaging of vessels within bones has proven challenging due to internal reflections of the
backscattered signal. Lower frequency and increased power transducers can penetrate
deeper into tissues and provide the internal visualization of bone; however, these imaging
systems have reduced resolution113 and increased heat tissue deposition.114,115 In addition
to the reduction in resolution and increased possibility of sample degradation (through
increased heat deposition), the typical contrast-to-noise ratio (CNR) within CEUS images
is rather poor, especially at resolutions necessary to distinguish between microvessels and
subchondral bone.
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Micro-computed tomography (micro-CT, Figure 1.4) is a ubiquitous imaging technique
routinely used for the visualization and characterization of bone95,116-118 and vessels (i.e.
angiography).119,120 Micro-CT is commonly used in the analysis and visualization of
dense x-ray attenuating objects, such as bone. However, visualization and detection of the
low x-ray attenuating vessels require the addition of an exogenous vascular contrast agent
(similar to micro-MRI and CEUS).121

Figure 1.4: Micro-CT scanner located at Robarts Research Institute.

In comparison to CEUS, the noise within micro-CT images is reduced and on par with
those acquired with micro-MRI. Therefore, with an already well-established ability to
characterize and visualize bone and vessels, micro-CT is the ideal imaging methodology
for the in vitro and ex vivo study of changes to the subchondral bone and its associated
vascular networks during the initiation and progression of OA.
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1.4 Micro-Computed Tomography Analysis of MicroVasculature and Bone
Micro-CT acquisition involves the projection of x-rays through a sample, where a
detector records the x-ray attenuation (i.e. x-ray absorption) along each ray path. Signal
intensity within micro-CT images is dependent on the electron density of the sample. The
generation of a micro-CT image involves the acquisition of hundreds of two-dimensional
(2D) projections at many view angles around the object of interest. Three-dimensional
(3D) image reconstruction is then carried out using established algorithms (such as
filtered back-projection, implemented in cone-beam geometry).122 Within the 3D volume,
each volumetric element (i.e. voxel) is assigned a CT number proportional to the linear
attenuation coefficient – of the material within that voxel.123
In practice, micro-CT is commonly used for the examination of objects with natural
endogenous contrast, resulting in easier visualization within CT images124– such as
bones,125-128 verification of medical apparatuses,129,130 geological and material
analysis.131-135 However, as previously mentioned, visualizing materials with lowelectron densities (i.e. soft tissues) is difficult and requires contrast enhancement via
exogenous agents.136

1.4.1

Contrast Enhancement

Visualization of materials with low x-ray contrast difference relative to their
surroundings (e.g. blood vessels within tissue) requires the addition of an exogenous
contrast agent.137,138 Clinically, an iodine-based vascular contrast agent is injected into
the blood stream to enhance the x-ray attenuation of perfused vessels (i.e. angiography).
Thus, the contrast-enhanced vessels can be easily visualized and automatically segmented
(based on greyscale values) from surrounding non-contrast enhanced soft tissues. Due to
insufficient spatial resolution and partial volume effects, perfused contrast-enhanced
vessels are indistinguishable and masked when present near and within dense x-ray
attenuating bone. Thus, iodine-based agents are unable to facilitate the distinction and
automatic separation of perfused vessels from nearby bone, when based on greyscale
values alone (Figure 1.5).139
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Figure 1.5: Images depicting the typical results of a CT angiogram of the legs of a patient. Iodine
vascular contrast enhancement of perfused vasculature (i.e. femoral artery) is easily distinguished
from surrounding soft tissue. However, as one can imagine, distinguishing perfused vasculature
surrounding dense skeletal structure (i.e. femur, tibia, and ankle) based on greyscale values is
extremely difficult. Modified with permission from Yamamoto et al., 2009.140 Copyright
Elsevier.

Pre-clinically, higher-electron density barium (Ba)- and lead (Pb)-based contrast agents
provide significantly higher x-ray attenuation than the iodine-based counterpart.141
However, the contrast enhancement, provided by Ba and Pb, exhibits similar greyscale
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values as cortical bone,142 hindering the automated separation of the perfused vascular
network within and around bone.
To overcome this challenge, the sample can be scanned with micro-CT before the
addition of the contrast agent (i.e. bone-only image) and following perfusion of the
contrast agent and decalcification of bone (i.e. vessel-only image).143,144 Combining the
two resulting scans would provide a visualization of the interaction between the perfused
vessels and bone. However, the main disadvantage of this methodology is the
susceptibility to improper image co-registration between the acquired scans, caused by
movement of vessels and tissues during perfusion and decalcification processes. The
resulting misalignments between the vascular network and bone may lead to
misinterpretations regarding the anatomical relationship between vessels and bone.
Fortunately, there does exist a micro-CT imaging technique that can non-destructively
and simultaneously acquire segmented volumes of soft tissue, bone and perfused vessels:
dual-energy micro-computed tomography.

1.4.2

Dual-Energy Micro-Computed Tomography (DECT)

Dual-energy micro-CT (DECT) is an imaging technique that can separate components
within a sample, based on their elemental composition. As the name infers, DECT
involves scanning specimens at two x-ray energies, followed by the application of
decomposition algorithms that exploit differences between the elemental specific x-ray
attenuation signatures of each component. With this approach, visually distinct and
quantifiable 3D volumes of each component can be obtained.142 The performance of
DECT and image decomposition can be further improved by tailoring the DECTacquisition parameters to the specific absorption K-edge of the material of interest.
When sufficient x-ray energy is present to exceed an elements’ unique absorption K-edge
energy (i.e. the x-ray energy required to eject an inner K-shell electron), a significant
increase in x-ray attenuation is observed. Image decomposition of the material-of-interest
can be significantly improved by tailoring and narrowing the low- and high-energy (i.e.
dual-energy) x-ray spectra around the element-specific distinctive x-ray attenuation spike.

13

Synchrotron radiation-based DECT (SRDECT) presents itself as an ideal DECT imaging
technique due to its ability to provide monochromatic x-ray energies.145,146 Synchrotron
facilities can provide x-rays of a single energy with high photon flux, resulting in
increased signal-to-noise, reduced noise, and a reduction in scan times.147 Additionally,
the sub-micron resolution148 can allow the resolution of smaller structures, and recent
developments detectors have allowed for larger field-of-views.149 While appealing, the
main drawbacks associated with SRDECT are: (1) limited number of synchrotron
facilities; (2) cost associated with travelling to these facilities; (3) competition for
beamtime; and (4) synchronization of biological experiments with available beamtime.
The use of pre-clinical micro-CT scanners for DECT analysis is a more practical
approach due to the wider availability of scanners (in comparison to synchrotrons) and
their current use in DECT research.150-152 However, optimizing the performance of DECT
on pre-clinical, gantry-based, cone-beam, micro-CT scanners has been challenging due
to: (1) lower x-ray tube potentials (90 kVp) which may limit the performance of DECT
on contrast agents of high-Z (i.e. Pb); (2) limited accessibility to micro-CT scanner
internal hardware to apply the necessary x-ray filtration to shape output x-ray spectra;
and (3) inherent gantry movements and non-reproducible bed micro-movements, which
may result in image misalignment.
Recent developments outlined throughout this thesis will demonstrate the methodologies
and techniques implemented to optimally perform DECT on a pre-clinical, gantry-based,
cone-beam, micro-CT scanner. We explain how to tailor the output x-ray spectrum of a
pre-clinical micro-CT scanner for a customizable novel ex vivo vascular perfusion
contrast agent. The combination of our contrast agent and DECT was then applied to
study the micro-vascular and subchondral bone differences within the hindlimbs of a
well-characterized surgically induced rat model of OA over the course of 8-weeks postoperatively.

1.5 Thesis Objectives and Hypotheses
In this thesis, we present the methodologies required to: (1) develop a novel pre-clinical,
DECT-compatible, ex vivo Er-based microvascular (i.e. capillaries of < 10 µm) perfusion
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contrast agent; (2) implementation of DECT on pre-clinical, gantry-based, micro-CT
scanners with a lower peak tube potential of 90 kVp; and (3) the combination of the
above techniques to study the concurrent microvascular and subchondral bone changes
that may occur during the initiation and progression of OA in a well-characterized
surgically induced rat hindlimb model of OA (i.e. ACLX + PMM). The ultimate results
of each Chapter are summarized as follows.
In Chapter 2, we describe and characterize a novel DECT-compatible erbium (Er)-based
ex vivo vascular perfusion contrast agent. Ultrasonic cavitation was employed to create a
colloidal suspension of nanoparticle-sized aggregates of erbium oxide (Er2O3) suspended
within a two-part silicone elastomer carrier. Intact mice were perfused post-mortem with
our Er-based suspension to evaluate its efficacy as a vascular perfusion contrast agent.
Micro-CT scans (50 µm isotropic voxel spacing) of Er-perfused mice confirmed a
significantly higher contrast enhancement of vessels when compared with nearby dense
bone and with a commercially available Pb-based contrast agent. High-resolution microCT scans (5 µm isotropic voxel spacing) of well-characterized mouse kidney vasculature
verified the ability of the novel vascular contrast agent to perfuse the smallest vessels (i.e.
capillaries, < 10 µm).
In Chapter 3, we outline the methodology required to customize and optimize DECT for
our novel Er-based contrast agent (Chapter 2) in a way that is compatible with the large
installed base of pre-clinical gantry-based cone-beam micro-CT scanners with a 90 kVp
operating x-ray tube potential. This chapter outlines the required aspects for the optimum
performance of DECT: (1) choosing and fabricating appropriate x-ray filtration and
acquisition protocols to match Er’s absorption K-edge; (2) fabrication of an automated
filter-exchange mechanism for the automated acquisition of DECT images; and (3)
accurate sub-voxel image co-registration using fiducial markers. The optimized DECT
was demonstrated through the automated decomposition of several Er-perfused rat
hindlimbs into distinct and quantifiable 3D volumes of soft tissue, bone, and vessel.
In Chapter 4, the combination of our novel Er-based contrast agent (Chapter 2) and
optimized DECT (Chapter 3) was utilized to simultaneously study the subchondral bone
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and microvessel changes during the initiation and progression of OA within a wellcharacterized surgically-induced rat hindlimb model of OA (i.e. ACLX + PMM). Rats
(N = 56) were split into two surgery groups (ACLX + PMM or sham surgery) and for
various time points (T = 0, 1, 2, 4, and 8 weeks) post-surgery. Quantitative analysis of
vessel and bone changes was confined to the distal femoral epiphysis and proximal tibial
epiphysis regions, due to their proximity to the cartilaginous surface and ease of
contouring regions of interest within the CT data.
In Chapter 5, we present a summary of the main goals and findings from Chapters 2 – 4.
Additionally, we review future directions and research that may benefit from the work
presented within this thesis.
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Chapter 2

2

Erbium-Based Perfusion Contrast Agent for SmallAnimal Microvessel Imaging

2.1 Introduction
It is increasingly important in pre-clinical research to study the vasculature in both soft
tissue and bone.1-5 This includes visualization, quantification, and characterization of
microvessels (i.e. vessels less than 10 µm in diameter). Micro-computed tomography
(micro-CT) of intact ex vivo small animals can provide images with spatial resolution
better than 5 µm.6-8 However, blood-filled vessels lack inherent radiographic contrast,
requiring the use of an exogeneous contrast agent that can pass through capillaries and be
retained within the vascular system. The increased contrast provided by such an agent
facilitates automated (or semi-automated) segmentation (i.e. separation) of the perfused
vasculature from surrounding tissues.
The performance (sensitivity, specificity, and accuracy) of vessel segmentation
algorithms has been shown to be dependent on the contrast-to-noise ratio (CNR, defined
as the ratio of the vessel signal to surrounding tissue signal) between the contrastenhanced vasculature and surrounding tissue in the micro-CT image.9 Higher CNR
results in a more robust and objective classification of the perfused vessels, leading to a
more accurate assessment of their microarchitecture. The CNR can be increased by either
reducing background noise or increasing the signal intensity within the vessel. However,
decreasing micro-CT image noise is typically impractical, as it is achieved through much
longer scan times.10 Therefore, the most effective method to increase vessel CNR is to
increase the contrast within the vasculature, using a radiopaque exogeneous contrast
agent.
Several formulations of exogeneous vascular contrast agents are commonly available.
Most clinical contrast agents for in vivo use are iodine-based. However, their small
molecular size of < 800 Da, results in rapid clearance (i.e. within minutes) via the
kidneys.11,12 Even in post-mortem studies with increased iodine concentrations and scan

29

times, the short retention time of these iodine-based agents make them unsuitable for
micro-vessel studies. Pre-clinical exogeneous agents, of larger molecular sizes (i.e. >
1100 Da), can remain within the blood pool for hours.13,14 These contrast agents are
typically iodine-, barium-, or lead-based and have been used effectively to study vessel
microarchitecture in the heart,15,16 kidney,17,18 tumours,19,20 nerves,21-23 and long
bones.24,25 However, these pre-clinical contrast agents do not exhibit optimal x-ray
absorption (and hence do not optimize CNR) on a large installed base of micro-CT
machines that typically operate at a maximum of 90 kilo-electron volts (keV).
X-ray absorption, responsible for observed contrast within x-ray images, is influenced by
the K-edge of the contrast material (i.e. the energy required to eject an inner K-shell
electron). The K-edges for common pre-clinical contrast agents are 33 keV for iodine,
37.4 keV for barium, and 88 keV for lead. These K-edge energies are not optimally
matched for typical micro-focus tubes operating at a peak potential of 90 kVp, as the Kedge energies are located either at the low- or high-energy range of the output spectrum
of the tube. Ideally, a contrast agent with a K-edge closer to the mean energy of the
output spectrum of these micro-CT machines (~42.7 keV) would provide enhanced x-ray
absorption.
The lanthanide erbium (Er), with a K-edge at 57.5 keV, would provide the contrast
necessary for micro-CT scanners operating at 90 kVp. An Er-based contrast agent would
also provide an additional benefit for dual-energy micro-CT studies, which require CT
scans above and below the K-edge of the material of interest.26 In this study, we describe
a novel contrast agent based on erbium oxide (Er2O3) nanoparticles (nominal diameter of
~50 nm), and illustrate a process by which Er2O3 nanoparticles form a colloidal
suspension in a continuous-phase fluid (i.e. two-part liquid silicone elastomer). This
methodology of contrast agent fabrication resulted in a high atomic number (and
consequently highly x-ray attenuating) ex vivo vascular perfusion contrast agent, with
sufficiently low viscosity (19.2 mPa∙s) to ensure the perfusion of the micro-vascular
network (< 10 µm).
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Using single-energy micro-CT, we demonstrate the efficacy of the custom contrast agent
in a post-mortem murine model. The contrast agent perfused the smallest vessels in a
mouse kidney (i.e. glomerular capillary bundles), and provided increased CNR with
respect to surrounding tissues, facilitating the visualization of micro-vessels with
diameter < 10 µm. The Er-based contrast agent provided a greater CNR than
commercially available agents, while also possessing a more appropriate absorption Kedge energy (57.5 keV). The resulting increase in vessel contrast would enhance the
performance and automation of segmentation algorithms in all types of vascular networks
and small-animal models (for both single- and dual-energy studies). This approach will
be applicable in many pre-clinical studies, including musculoskeletal, cardiovascular,
neurovascular, and oncological research programs.

2.2 Materials and Methods
2.2.1

Er-based Contrast Agent Preparation

Erbium oxide (Er2O3) nanoparticles (NPs) were chosen as the main constituent of the
contrast agent, due to their high x-ray attenuation and availability in a nanoparticulate
powder (nominal diameter ~ 50 nm). To deliver the Er2O3 NPs throughout the vascular
network, a commercially available two-part silicone elastomer (commonly used for
vascular perfusion, Microfil MV-132, Flowtech Inc., Carver, MA, USA) was chosen as
the carrier matrix. Uncured, this silicone elastomer has a manufacturer-reported viscosity
of 20 mPa∙s and when cured, the silicone matrix entrains the suspended Er2O3 NPs to
form a stable silicone cast of the perfused vasculature. Initial experiments revealed
difficulties incorporating the Er2O3 NPs within the two-part silicone elastomer. Analysis,
via confocal fluorescence microscopy, of the uncoated Er2O3 powder revealed the
tendency of the NPs to naturally aggregate into clusters > 1 µm, due to van der Waals
forces – nanoparticulate powders have been shown to naturally clump and form much
larger particle sizes when left uncoated or untreated.27,28 Large aggregates such as these
could clump together and prevent the perfusion of arterioles and capillaries, inhibiting
perfusion of the venous system. Thus, to address the fact that uncoated nanoparticles tend
to aggregate into large clumps (i.e. > 100 μm) a method was devised to ensure the size of
the Er2O3 NPs in the final product remained smaller than 100 nm, as follows.
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2.2.2

Er2O3 NP silicone elastomer suspension

Uncoated Er2O3 NPs of ~50 nm nominal diameter (Nanostructured and Amorphous
Materials, Houston, TX, USA) were ground using a mortar and pestle for ~ 5 minutes to
break down large aggregates. The ground powder was then mixed with an additive-free
clear two-part silicone elastomer (Microfil MV-132, Carver, MA, USA), which is mixed
in a ratio of two parts MV-Diluent to one part MV-132. To prepare 30 mL of contrast
agent, 4.0 g of ground Er2O3 (i.e. 13.3% w/v) was added to 17.47 mL of MV-Diluent and
8.73 mL of MV-132; the remaining 3.8 mL was comprised of the curing agent described
below, which was added immediately prior to perfusion into the animal. The uncured
suspension of Er2O3 powder and silicone elastomer was probe sonicated (Branson Digital
Sonifier 450D, standard 13 mm tapped horn, Crystal Electronics, Newmarket, ON, CAN)
for a total of 35 minutes with 25% amplitude and a duty cycle of 30 s ON to 10 s OFF.
Due to the intense heat generated during sonication, the samples were immersed in an ice
bath and sonication was performed in three intervals interspersed with 5 – 10 minute
cool-down periods. The Er2O3 NP silicone elastomer suspension was prepared several
hours prior to perfusion, to allow particle aggregates to settle, then decanted prior to use.
If prepared further in advance, sonication of the suspension of 5 - 10 minutes is required
to ensure particle re-suspension.

2.2.3

Curing agent

To facilitate consistent and controlled curing of the Er2O3 NP silicone elastomer
suspension, a tin-based curing agent was prepared in-house. The curing agent comprised
a solution of 40% (w/w) dibutyltin dilaurate (Sigma Aldrich, St. Louis, MI, USA) in
tetraethyl orthosilicate (Sigma Aldrich, St. Louis, MI, USA), which was mixed using a
magnetic stirrer for several hours until it became a homogeneous pale-yellow transparent
solution.

2.2.4

Er-based Contrast Agent Characterization

Particle and aggregate sizes of the “raw” and sonicated Er2O3 powder were evaluated
visually using confocal fluorescence microscopy. Prior to sonication, drops of raw Er2O3
powder mixed within the two-part silicone elastomer were dispensed on a glass bottom
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microwell dish (MatTek Corporation, Ashland, MA, USA). Following sonication, drops
of the prepared Er-based suspension were placed on a separate microwell dish. Samples
were analyzed using confocal fluorescence microscopy (Leica DMi8, Wetzlar, Germany),
an Ar 488 nm laser for excitation, and emission bandwidths of 493 – 739 nm. To
visualize particle sizes within the non-sonicated “raw” sample and sonicated suspension,
a 20x (HC PL APO CS2 20x/0.75 DRY) and 63x (HC PL APO CS2 63x/1.40 OIL)
objective lens were used, respectively.
Dynamic Light Scattering (DLS) was used to quantify the size distribution of the
prepared Er-based suspension. A 10% (v/v) dilution of the suspension in MV-Diluent
was prepared and analyzed with DLS (ZetaSizer Nano instrument, Malvern Instruments
Ltd, Malvern, UK). Measurements were performed at room temperature (25°C) in a
quartz cuvette (1 mg/mL).
The viscosity of the contrast agent was measured using a lab-based Modular Compact
Rheometer (MCR 302, Anton Paar, Graz, Austria); the measured viscosity was used to
correct the DLS measurements.

2.2.5

Animals

All animal studies were approved by the Animal Use Subcommittee at Western
University (protocol #2015-018). Five male C57BL/6 mice (~30 g) were used for this
study. The mouse model was selected to demonstrate the capability of the Er2O3 contrast
agent to perfuse the microvasculature of the smallest of the commonly used small animal
models. Anesthetized mice were exsanguinated with sterile saline followed by perfusion
with the Er-contrast agent. To prevent blood clot formation during exsanguination, sterile
0.9% (w/v) saline was heparinized to 0.4% (1 mL of heparin (Sandoz, QC, CAN) in 250
mL saline). Sterile tubing (Baxter Canada, Mississauga, ON, CAN), 1.8 m in length, was
used to connect the saline bag to a blunted 21G × 3/4” butterfly catheter (BD, Franklin
Lakes, NJ, USA). The saline IV bag was hung 127 cm above the surgery table, thereby
providing a pressure of 94 mmHg. Five minutes prior to the start of the procedure the
mice were given a 100 μl intraperitoneal injection of heparin. After induction of
anesthesia (3% isoflurane (Baxter Canada, Mississauga, ON, CAN) in O 2 at a rate of 2
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mL/min) an incision was made along the thoracic cavity exposing the heart. The butterfly
catheter was carefully inserted into the left ventricle parallel to the septum. A drop of
cyanoacrylate (Krazy Glue, Elmer’s Products, Atlanta, GA, USA) was applied at the
entry point of the catheter into the left ventricle to avoid accidental piercing of the
septum. The right atrium was clipped to allow for circulatory system drainage. The
heparinized saline solution was perfused throughout the circulatory system for 10
minutes to ensure complete removal of the blood.
During saline perfusion, 3.8 mL (12.7% v/v) of curing agent was added to 36.2 ml Er2O3based silicone elastomer suspension and vortexed (VWR® Fixed Speed Vortex Mixer,
Radnor, PA, USA) continuously for 8 minutes. The contrast agent was injected into an
empty IV bag (with separate 1.8 m of surgical tubing) and hung 160 cm above the mice
(129 mm Hg). While this value is greater than the mean arterial pressure (MAP) of mice
(~ 103 mm Hg),29,30 it was chosen to ensure complete perfusion of the animal before the
contrast agent cured. Furthermore, the perfusion pressure used in this study is
significantly lower than the >150 mmHg used in prior studies using the lead-based
Microfil agent.22,31-33 Perfusion at a pressure more closely matched to peak systolic
pressure (i.e. ~120 mmHg) reduces the risk of vascular dilation and capillary rupture. The
contrast agent was let to freely perfuse through the animal until completely cured, which
occurred approximately ~35 minutes after start of perfusion. Following contrast agent
curing, mice were placed in 10% neutral buffered formalin overnight, prior to micro-CT
scanning.

2.2.6

Data Collection and Analysis

Whole body mouse scans were acquired with a pre-clinical micro-CT scanner (Vision
120, GE Healthcare, London, ON, CAN). The scan parameters were 90 kVp (no added
filtration), 40 mA, 900 views, 0.4º increment angle over 360º, geometric magnification of
1.13, 16 ms exposure, resulting in a total exposure time of 14.4 s and 576 mAs. Including
the time required for gantry motion and recording of image projections, the total
acquisition time was 5 minutes. The projection images were binned 2 × 2 prior to
reconstruction for a final isotropic voxel spacing of 100 μm.
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Higher resolution scans of the hindlimb regions were acquired on a specimen scanner
(Locus, GE Healthcare, London, ON, CAN) using a 3 hr scan protocol (900 views, 80
kVp, 80 μA, no added filtration, 0.4° increment angle over 360º, geometric magnification
of 1.41, 15 frame averaging, and 2 × 2 binning for a final isotropic voxel spacing of
40 μm). To prevent sample motion during these high-resolution image acquisitions, the
perfused mouse was placed in a 50 mL tube.
Confirmation of perfusion of micro-vessels (i.e. < 10 µm) was achieved by highresolution single-energy micro-CT. Fabricated micro-vessel constructs, or synthetic
capillaries have been utilized to evaluate micro-vessel perfusions in the past,34,35 but
fabricating synthetic vessels with diameters on the order of 10 µm remains technically
challenging. Fortunately, the mouse kidney is a well-characterized organ system, with
known vessel diameters ranging from the renal artery (~0.3 mm) to capillaries
(~10 µm).36,37 The kidney contains many glomeruli (responsible for the waste removal
and blood filtering), which are comprised of capillaries in a bundle of ~75 µm diameter.38
Therefore, an excised Er2O3-perfused kidney was embedded in paraffin in a 1.2 mL tube
(Corning®, Corning, NY, USA) and scanned with a specimen scanner (Locus SP, GE
Healthcare, London, ON, CAN), using a 16 hr protocol. Scan parameters were 80 kVp,
80 μA, 900 projections, no added filtration, 0.4° increment angle over 360º, geometric
magnification of 3.83, 14 frame averaging, and 1 × 1 binning for a final isotropic spatial
resolution of 4.8 μm.
The micro-CT scanners used in this study were all equipped with a CsI-based energyweighted detector. It has been shown that the peak response of these detectors39 is very
close to the absorption K-edge of Er (57.5 keV), making them ideally suited for detection
of an Er-based contrast agent.
Each of the scans contained calibrators of water and air, which were used for image
calibration and conversion into Hounsfield units (HU). This allowed us to quantify the
amount of contrast enhancement of perfused vasculature, based on the CT signal level in
HU within various organs throughout the vascular system. Using 3D visualization and
analysis software (MicroView, GE Healthcare, London, ON, CAN), regions of interest
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(ROI) 500 × 500 × 500 μm were generated in each region and the mean HU values
recorded. Specifically, for all mice, the mean HU was determined from the heart (left
ventricle), testes, and inferior vena cava (IVC), as they represented the beginning,
middle, and end of the perfusion pathway, respectively. The CT signal levels within the
selected organs were compared to cortical bone within the diaphysis region (i.e. the
densest endogenous contrast) and a commercially available lead-based contrast agent. A
rat hindlimb previously perfused with the widely used and commercially available leadbased contrast agent (Microfil MV-122, Flowtech Inc, Caver, MA, USA) was scanned
using the 100 µm acquisition protocol.
All statistical analyses were performed using Prism 6 (GraphPad Software Inc, La Jolla,
CA, USA). Repeated measures ANOVA was used to test for statistical differences
between all Er-based contrast-enhanced regions (i.e. heart, testes, IVC) and cortical bone.
In a separate test, one-way unpaired ANOVA was performed to compare the mean
attenuation in Er-perfused vessels against cortical bone and the Microfil MV122-perfused
rat femoral artery. Statistical differences were noted if a p < 0.05 was achieved.

2.3 Results
2.3.1

Efficacy of an ex vivo Er-based contrast agent for vascular
perfusion

An effective pre-clinical post-mortem x-ray compatible vascular contrast agent must be
comprised of small, x-ray attenuating particles homogeneously suspended within a lowviscosity medium. These characteristics will ensure uniform contrast enhancement of
perfused vasculature, including micro-vessels with diameter < 10 µm (i.e. capillaries).
Automated segmentation algorithms, which are typically based on grey-scale levels,
require homogeneous perfusion of micro-vessels to effectively separate perfused
vasculature from surrounding tissues, so it is essential to employ an appropriate particle
size, uniformly distributed in the carrier medium.
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Ultrasonic cavitation (sonication) was used to successfully break up large aggregates of
Er2O3 to nm-sized aggregates, which could be homogeneously incorporated within the
two-part silicone matrix. Following intense sonication, a visually homogeneous
suspension of 13.3% w/v Er2O3 within the two-part silicone elastomer was achieved. The
Er2O3 NPs were found to remain in suspension for several days, allowing for the contrast
agent to be prepared several days prior to use. Confocal fluorescence microscopy visually
confirmed that the size of the sonicated nanoparticles within the Er2O3 contrast agent
suspension (Figure 2.1B) were less than 100 nm – a size that can pass easily through the
micro-vessels of any vascular system.

Figure 2.1: Confocal fluorescence microscopy images of (A) non-sonicated raw Er2O3 powder
naturally aggregated to large micro-sized (> 10 µm) particles when mixed within the two-part
silicone elastomer, making the suspension not suitable for microvascular perfusion. However,
with sonication, nano-sized (~70 nm) particles were achieved (B).
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The ability of a contrast agent to perfuse the microvasculature also depends on its
viscosity. Measuring the viscosity of the uncured Er-based contrast agent – at 19.2 mPa∙s
– demonstrated agreement with the 20 mPa∙s viscosity reported by the manufacturer of
the two-part silicone elastomer, confirming that the uncured Er2O3 contrast agent is able
to pass through small vessels under standard perfusion pressures.
Based on the measured viscosity of 19.2 mPa∙s, the DLS measurement reported a
Gaussian particle size distribution with mean hydrodynamic diameter of 64.8 nm,
standard deviation of 11.1 nm, and a range from 44 to 122 nm (Figure 2.2 and A.1).
Measurements of particle size and carrier viscosity indicated that the prepared Er2O3
suspension should easily pass through micro-vessels; this aspect of performance was
further evaluated by micro-CT imaging of intact perfused mice.

Figure 2.2: Dynamic light scattering (DLS) results demonstrating the particle size distribution
of a sample of the Er2O3 contrast agent. Average particle size is 64.8 ± 11.1 nm. Results of a
suspension that was mixed and subsequently stored for 2-years are shown in A.1.
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Whole Er2O3-perfused C57Bl/6 mice scanned with 50 µm isotropic voxel spacing, and
rebinned 2 × 2 to a final resolution of 100 µm, revealed a uniform and homogeneous
distribution of the cured Er2O3 contrast agent within the vasculature throughout the entire
perfused mouse (Figure 2.3). The vasculature displayed enhanced contrast in comparison
to surrounding tissues throughout an intact animal; importantly the attenuation of the
contrasted vessels was higher than that of bone.

Figure 2.3: Rebinned 100 µm voxel images where the (A) Maximum intensity projection (MIP)
of a whole-body perfused mouse demonstrates that the attenuation of the Er2O3 contrast agent in
the vasculature is higher than the mouse’s skeletal structure. Quantitative measurements of
attenuation (in HU) were obtained from regions drawn within heart (B), testes (C), inferior vena
cava (D), and cortical bone (E).
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Scans of Er-contrast-perfused hindlimbs were acquired with 20 µm isotropic voxel
spacing and subsequently rebinned 2 × 2 for a final resolution of 40 µm (Figure 2.4), to
observe the smaller vasculature next to the dense bony structures of the femur and tibia.
From these results, we were able to clearly see a feeding artery that runs within (Figure
2.4A) and along (Figure 2.4B) the entire length of each long bone. At this higher
resolution, smaller structures such as a foramen (i.e. an opening for blood vessels to enter
bone) can be visualized (Figure 2.4C). The ability to differentiate the foramen from the
vessel running through it is particularly noteworthy, as this is not possible with other
contrast agents that have lower attenuation coefficients. The observed perfusion of the
venous system (Figure 2.4A yellow arrows) suggests successful perfusion of the
capillaries, which is further supported by the lack of visible contrast-agent pooling within
the interstitial space (pooling might have been observed if over-pressurization during
perfusion had caused micro-vessel rupture).

Figure 2.4: Multi-planar reformatted images at 40 µm, resulting from 2 × 2 rebinning of 20 µm
acquired micro-CT scans, clearly depict the ability to visualize the extent of the nutrient arteries,
which run along the tibia and femur. Red arrows highlight the nutrient arteries in cross-section in
(A) and along their entire length in (B). At this resolution the depiction of parallel arteries and
veins (yellow arrows) indicates successful perfusion through the capillary network. The ability to
visualize vessels as they pass through a foramen (green arrows) into bone is depicted in (C).
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2.3.2

Visualization of capillary bed perfusion

The results of the high-resolution micro-CT scan revealed that the Er2O3 contrast agent
successfully perfused the entire continuous, well-ordered vascular tree of the kidney
(Figure 2.5). The contrast enhancement of the vasculature was sufficiently high, such that
a single grey-scale threshold separated perfused vasculature from surrounding tissues,
allowing for the generation of 3D images of the kidney vessel microarchitecture
(Figure 2.5B). The virtual Er2O3 vascular “cast” (Figure 2.5A and B) showed complete
perfusion from the abdominal aorta (i.e. a main feeding vessel) down to the 6th and 7th
arterial branches (i.e. glomeruli afferent arterioles). Previous research has shown that
mouse glomeruli afferent arterioles can be as small as ~13 µm;36 thus, visualization of
individual glomeruli (i.e. several capillaries) suggests that our contrast agent is able to
perfuse structures < 13 µm (Figure 2.5C and D). While previous research has shown
perfusion of the kidney down to the afferent arterioles36,40-42 using a commercially
available lead-based contrast agent, the main advantage of the Er2O3 – based contrast
agent is its ability to provide higher contrast and CNR.
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Figure 2.5: (A) MIP of an entire mouse kidney and attached adrenal gland (arrow) perfused with
the new Er contrast agent. (B) 3D rendering of the perfused kidney with a plane cut to
demonstrate an entire intact vascular tree. (C) magnified 0.35 mm thick slice MIP of the area
outlined in red in (A), demonstrating 6-7th level arterial branching. (D) 3D rendering of the
terminal arteriole branches, ending in the glomeruli (the kidney’s spherical capillary bed). G =
glomeruli; AF = afferent arteriole; EF = efferent arteriole; RA = cruciate radial artery; RV =
cruciate radial vein; AA = arcuate artery; AV = arcuate vein; and VR = vasa recta.
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2.3.3

Contrast enhancement provided by the Er-based contrast
agent in micro-CT

The measured mean CT values for the heart (4094 ± 264 HU), testes (4107 ± 182 HU),
and IVC (4001 ± 305 HU), compared in Figure 2.6, showed no significance difference
(p = 0.3940) between these three regions. On the other hand, the mean signal from
cortical bone (2359 ± 207 HU) and the lead-based contrast agent Microfil MV-122 (2683
± 77.6 HU) were significantly lower than the signal from the Er contrast-agent perfused
vasculature (p <0.006 and p <0.0001 for bone and Microfil, respectively). The
approximately 1400 HU difference in signal between that provided by the Er2O3 - based
contrast agent and cortical bone will aid in facilitating the automatic segmentation of
vessels from surrounding bone, which is not possible when commercially available
contrast agents, such as Microfil MV 122, are used.

Figure 2.6: Heart, testes, and inferior vena cava (IVC) were chosen to represent the start, middle,
and end of the perfusion route. The attenuation (HU) of the Er2O3 - based contrast agent in all
three regions was significantly higher than that of cortical bone (p < 0.006, repeated measures
ANOVA). Importantly, the attenuation of the Er2O3 – enhanced vasculature was significantly
higher than that commercially available lead-based Microfil MV122 (one-way ANOVA,
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p < 0.0001), while there was no difference between Microfil MV122 and cortical bone
(p > 0.9999).

2.4 Discussion
We have demonstrated a methodology for the homogeneous incorporation of Er2O3
nanoparticles within a two-part silicone elastomer, forming a colloidal suspension
capable of providing high x-ray attenuation that can facilitate the visualization and
characterization of micro-vessels within a small animal model. In this study, we
characterized and investigated the capabilities of the custom ex vivo Er-based vascular
perfusion contrast agent.
Ultrasonic cavitation successfully broke down large naturally occurring Er2O3 aggregates
(i.e. > 100 µm) into nm-sized particles (Figure 2.1B and 2.2) suspended within a silicone
carrier. The prepared suspension was determined to possess low viscosity and a narrow
particle size distribution that would facilitate the perfusion of intact whole-body mice
(Figure 2.3). Micro-CT scans acquired with both 50 and 20 µm isotropic voxel spacings
revealed whole-mouse perfusion and higher-ordered vascular branching (i.e. 1st to 3rd
order) and visualization of vessels within bone (Figure 2.3 and 2.4). High-resolution
scans with 5 µm spatial resolution demonstrated well-characterized vascular
microarchitecture within a perfused kidney, with observed vascular filling down to
vessels < 13 µm in diameter and contrast enhancement of capillary beds (i.e. glomeruli,
Figure 2.5). Additionally, the attenuation of the Er-based contrast agent was found to be
significantly higher than that of cortical bone (i.e. the densest naturally occurring
substance within our samples) and the commonly used lead-based Microfil (MV-122)
vascular contrast agent (Figure 2.6). This study clearly demonstrates the efficacy of the
custom Er-based suspension as an ex vivo micro-CT vascular perfusion contrast agent.
An important benefit of the presented Er-based contrast agent is an x-ray attenuation
coefficient that is significantly higher than that of both bone and other existing contrast
agents. This difference facilitates the separation of microvessels from both soft tissue and
bone in the images and can also result in a reduction of scan time. While shorter scans
result in a greater amount of noise,10 the higher contrast between the Er contrast agent
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within the vasculature and surrounding tissue ensures that CNR remains high despite the
shorter scan times. The approach used to incorporate the Er nanoparticles within the
suspension (i.e. ultrasonic cavitation) renders the approach amenable to the production of
custom contrast agents of varying elemental compositions and concentrations.
Furthermore, silicone-compatible colorants can also be introduced within the silicone
media to allow for the customization of the contrast agents’ visual appearance against
tissue; this may be useful for macroscopic visualization and post-mortem histological
analysis.
In the current implementation, each working volume of contrast agent (i.e. 30 ml) is
prepared individually, requiring approximately one hour of operator time. Larger
volumes of contrast agent could be prepared in advance, with the curing catalyst being
added just prior to usage. In this case, additional sonication may be required to ensure resuspension of aggregated particles (Figure A.1).
As with other cast-forming contrast agents (e.g. Microfil) the new Er-based contrast agent
is limited to applications of post-mortem vascular analysis at study endpoints. This
limitation requires that larger cohorts of animals are needed to assess changes to the
vasculature over periods of time. An in vivo contrast agent would make investigations
with reduced sample size possible and allow for the study of vascular changes within the
same animal over time; however, development of an in vivo contrast agent is not within
the scope of this study. Currently, there exist in vivo contrast agents that reside within the
blood pool for extended periods of time;43,44 thus, we expect that the incorporation of Er
into an in vivo agent is possible.

2.5 Conclusions
We have demonstrated the effectiveness of an Er-based suspension as a single-energy xray vascular contrast agent that significantly enhances the contrast – in comparison to
surrounding dense bone and commercially available lead-based contrast agents (Figure
2.6) – of perfused vasculature within small animals (Figure 2.3-2.5). With an absorption
K-edge at 57.5 keV, the Er-based contrast agent is also ideally suited for dual-energy
micro-computed tomography (DECT) on a large installed base of high-resolution pre-
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clinical micro-CT machines that operate at up to 90 kVp. The combination of the Er2O3based vascular perfusion contrast agent with optimized DECT scan protocols and spectral
shaping (using x-ray filtration) would facilitate rapid and automatic quantitative
segmentation of perfused vasculature from surrounding tissues,26 a process that is
otherwise difficult due to partial volume effects that can limit traditional single-energy
CT scans. Dual-energy CT-based material separation has been shown to be beneficial in
studying a range of diseases in clinical applications (i.e. gout, cardiovascular, and
cancer),45-47 by allowing for the quantitative separation of the material of interest from
surrounding tissues. The novel contrast agent that we describe has the potential to provide
these advantages of DECT-based quantification and segmentation for pre-clinical
investigations of vascular changes in small-animal models; this concept will be explored
in Chapters 3 and 4.
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Chapter 3

3

Dual-Energy Computed Tomography for a GantryBased Pre-Clinical Cone-Beam Micro-CT Scanner

3.1 Introduction
Micro-computed tomography (micro-CT) is widely utilized in biological studies for its
capability of providing high-resolution images of contrasting tissues. Attenuation within
micro-CT images is dependent on the materials’ effective atomic number (i.e. Z, electron
density), where higher Z materials (i.e. higher electron density) will exhibit higher x-ray
attenuation due to photoelectric absorption.1,2 For biological samples, bone can be easily
visually separated from surrounding soft tissues (i.e. muscle, fat, etc.) due to its
composition. However, discrimination between soft tissues is difficult, due to their
relatively similar electron densities.3 To enhance the visualization of soft tissues, tissuespecific exogeneous contrast agents are commonly required.4,5 Vascular contrast agents
(i.e. angiography), are routinely used to facilitate the visualization and distinction of
perfused vasculature from surrounding non-contrast enhanced soft tissues.6
Clinical angiography typically employs the use of iodine-based contrast agents.7-9 X-ray
images of perfused vasculature are markedly different – due to the increased contrast –
from surrounding soft tissue, allowing for the automatic segmentation of contrastedvessels based on greyscale values alone.10 However, due to the dilution of injected
iodine-based contrast agents and its diffusion within the blood stream, the contrast
enhancement of vessels is often masked by nearby dense bone. For in vitro and ex vivo
applications, more highly x-ray attenuating vascular agents such as lead-based silicone
elastomers (Microfil MV-122, Flowtech, Inc., MA, USA) can be utilized.11 Nonetheless,
the mean CT signal level of perfused vessels appears similar to cortical bone, hindering
their automatic separation based on greyscale values.5,12
Dual-energy micro-CT (DECT) is an x-ray imaging technique that can facilitate the
automatic decomposition and segmentation of materials based on their elemental
composition. Dual-energy CT is used clinically for angiography13 and kidney stone
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identification.14 As the name implies, DECT involves scanning a sample at different
energy spectra – achieved through differing acquisition protocols. Each material exhibits
a unique elemental x-ray attenuation signature; thus, within composite samples, DECT
decomposes each material based on their differential contrast at two different x-ray
energies. The performance and image decomposition of DECT can be further improved if
the dual-energy spectra are tailored to a material’s absorption K-edge.
Every material possesses a unique absorption K-edge energy (i.e. the x-ray energy
required to eject an inner K-shell electron), which leads to a significant increase in x-ray
attenuation when x-ray energies are above the K-edge energy. Dual-energy CT performed
with mean spectral x-ray energies above and below the K-edge of interest takes
advantage of this increased attenuation to improve the decomposition of materials of
interest. There are multiple avenues to performing DECT, whether it is through fast kVswitching,15,16 dual-source,15 or dual-detector CT scanners.17 However, the large installed
base of conventional pre-clinical micro-CT scanners are limited to scanning at a single xray energy at a time. The inherently polychromatic nature (i.e. implement with a broad xray spectrum) of these micro-CT scanners requires the careful selection of dual-energy
acquisition protocols, as large amounts of spectral overlap will reduce the effectiveness
of DECT decompositions.
Spectral separation between the low- and high-energy images can be achieved through
spectral shaping with differential added filtration to optimize the performance of
DECT.18-21 This has been successfully shown in previous research,5 where copper and
lead foils were utilized to facilitate the necessary spectral separation, resulting in the
DECT decomposition of a rat hindlimb (perfused with a lead-based contrast agent) into
separate images of bone and vasculature. However, a limitation associated with the use of
a lead-based dual-energy contrast agent is that the high K-edge energy of lead (88 keV)
necessitates the use of a high x-ray tube potential (e.g. 140 kVp) to achieve adequate
spectral separation.5 However, many pre-clinical micro-CT scanners are limited to
maximum tube potentials of approximately 80 – 90 kVp, which reduces the effectiveness
of DECT with Pb-based contrast agents (due to limited photon flux above the K-edge at
88 keV).
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A DECT-compatible erbium (Er)-based ex vivo vascular perfusion contrast agent has
been previously developed and characterized.22 The Er-based suspension is ideally suited
for DECT as its absorption K-edge (i.e. 57.5 keV) is located close to the mean energy of
micro-CT scanners (~42.7 kVp) with a 90 kVp maximum tube potential. Nonetheless,
optimizing DECT for an Er-based agent requires spectral shaping tailored to erbium’s Kedge, through the addition of x-ray filtration. Typically, the low- and high-energy images
will be acquired sequentially, with different filters; this leads to the potential for
geometric misregistration between image volumes, due to non-reproducible scanner
gantry movements. It may therefore be necessary to implement a method of image coregistration between acquired low- and high-energy image volumes.
This study outlines the design, implementation, and evaluation of optimized DECT on a
pre-clinical cone-beam gantry-based micro-CT scanner. In this investigation, we describe
a technique for the fabrication of: (1) custom x-ray filters to facilitate the needed spectral
separation on pre-clinical high-resolution gantry-based micro-CT scanners; (2) fiducial
marker-based image co-registration to correct for inherent micro-CT scanner bed and
gantry movement between sequential scans; and, (3) a motorized filter-exchange
mechanism for automated DECT acquisition. The evaluation of DECT was visually and
quantitatively confirmed through the automated decomposition of rat hindlimbs –
perfused with an Er-based vascular contrast agent – into individual volumes of soft tissue,
bone, and perfused vessels. The combination of the readily available techniques and
materials outlined throughout this study will allow users of a large installed base of
micro-CT scanners limited to scanning at a single x-ray energy at a time to perform
optimized DECT.

3.2 Materials and Methods
3.2.1

Spectral Shaping and Modeling

X-ray spectra were modelled using a previously developed computational tool for x-ray
spectral simulation (Spektr 2.0).23 This model incorporated CT scanner-specific
parameters, such as target angle of 15°, source-to-isocenter distance of 22.59 cm,
additional anode inherent filtration equivalent to 1.0 mm Al (Dunlee, DU 404), and 2 cm
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Lexan. Spectra were modelled with varying thicknesses of x-ray filtering materials and
simulated at 0.5 kVp increments. All modelling and calculations were performed within
Matlab (R2016b, MathWorks Inc, Natick, MA, USA).
Selection of the optimal parameters for low- and high-energy DECT scans involves the
choice of x-ray energy (i.e. kVp), type of filtration (i.e. elemental composition), and
thickness of filtration. The process necessarily involves a balance between optimizing
x-ray photon flux while maintaining sufficient spectral separation. Added filtration is
used to increase the mean energy of the spectrum and to reduce the width of the
spectrum. In the absence of filtration (i.e. maximum photon flux), high signal-to-noise
(SNR) images can be acquired; however, the lack of spectral separation between the lowand high-energy spectra will reduce the accuracy of DECT decompositions – visualized
as misclassified voxels between decomposed volumes. Conversely, excessive filtration
will enhance spectral separation, yet the resulting diminished photon flux will result in
poor SNR images, again compromising DECT decomposition accuracy.
We chose 90 kVp as the tube potential for the high-energy spectrum, as the mean energy
of the unfiltered spectrum (~42.7 kVp) is close to erbium’s absorption K-edge (57.5
keV). Additionally, 90 kVp is typical the maximum tube potential of a large installed
base of laboratory micro-CT scanners. The low-energy spectrum was set at 70 kVp, to
provide efficient x-ray production and ensure adequate photon flux just below the
absorption K-edge of Er. With the low- and high-energy tube potentials selected, it was
necessary to choose materials for differential x-ray filtration to facilitate the spectral
separation required for optimized DECT.
To filter the high-energy spectrum, copper (Cu) was selected to preferentially attenuate
low-energy photons, thereby shifting the mean energy higher. In addition, copper is
available in foil-form at varying thicknesses and low cost; it is widely used as a x-ray
filter for both single-24-26 and dual-energy CT.5,27 To model the behavior of Cu, the x-ray
cross section of Cu was obtained from the National Institute of Standards and
Technology’s (NIST) online database. Using the modelled output x-ray spectrum of our
micro-CT scanner (GE Vision 120, GE HealthCare, London, Ontario), a total Cu path
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length of 550 µm was calculated for a photon flux reduction of 70% (Figure 3.1b).
Previous research with a rat hindlimb perfused with a Pb-based agent,5 has shown that a
70% photon flux reduction (i.e. 30% photon transmission) resulted in sufficient spectral
separation to facilitate the decomposition of DECT images into segmented bone and
perfused vessel images.
To filter the low-energy spectrum, we selected an Er-based filter, as it will inherently
attenuate photons above 57.5 keV. Using the cross-sectional values of Er from NIST, a
calculated Er thickness of 68 µm would provide a 50% photon flux reduction, generating
a photon flux similar to that of the filtered high-energy spectrum (Figure 3.1, bottom
panel).

55

Figure 3.1: Computer modelled spectral distributions of the chosen 70 and 90 kVp low- and
high-energy spectra, respectively. (Top panel) Results of the modelled unfiltered 70 and 90 kVp
spectra. (Bottom panel) Modelled spectra of the 70 and 90 kVp with the addition of filtration to
increase spectral separation and reduction of overall photon flux.

3.2.2

X-ray Filter Fabrication

The Cu and Er filters described above can be implemented on bench-top specimen microCT scanners by placing metal foils at the x-ray tube port, prior to the sample. However,
for use with gantry-based micro-CT scanners, it may not be possible or practical to
modify the system in this manner. The addition of a mechanism to mount the filters on
the tube port – and exchange them between scans – may interfere with the normal
operation of the scanner and gantry balance. For these reasons, we elected to implement
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an annular cylindrical filter that surrounds the scan bed yet fits within the scanner bore.
This approach to filtration avoids modifications to the scanner and is compatible with
gantry-based scanners.5 Although the annular filter acts through a combination of preand post-object filtration, it provides a total attenuation that is equivalent to a pre-object
filter of identical path length.
A high-energy Cu x-ray filter was fabricated from readily available Cu foil. Sheets of
0.08 mm Cu foil were wrapped around an acrylic annular cylinder, with dimensions of
8.2 cm outer diameter (OD) × 6.4 cm height (H) × 0.3 cm wall thickness (WT). These
dimensions were chosen to be slightly less than the maximum field-of-view (FOV) size
for the selected micro-CT scanner (Vision 120, GE HealthCare, London, ON, CAN),
facilitating the reconstruction of the entire x-ray filter and sample during DECTacquisitions. A total of three individual layers of Cu foil provided a total pathlength of
0.48 mm, resulting in a photon flux reduction of 66%. However, unlike the high-energy
x-ray filter, fabrication of the low-energy Er x-ray filter remained challenging, as
sufficiently large sheets of Er are not readily available and may be prohibitively costly.
Therefore, this led us to develop a new methodology, which allowed the creation of cast
nano-powder-incorporated resin-based annular filters; in our case, inexpensive erbium
oxide nanoparticles.
To craft a custom cylindrical Er x-ray filter, a master filter shape and its respective
negative silicone mold were required. The master cylindrical annular shape was
machined from a solid cylindrical aluminum stock (Al, Alloy 6061, McMaster-Carr,
Aurora, OH) till dimensions of 8.2 OD × 6.4 cm H × 0.3 cm WT were achieved. The
bottom-half of the mold was constructed by embedding the Al filter in a thin layer
(~ 1 cm) of sulfur-free clay (Monster Clay, OH, USA) within an acrylic “box”
(Figure 3.2b); exact box dimensions are not critical. Several registration keys, fashioned
from clay, were placed throughout the mold. The silicone elastomer mixture was
prepared as instructed by the manufacturer (Bluestar Silicones RTV 4420 QC, NJ, USA),
poured into the acrylic box and allowed to cure (~1 hr, Figure 3.2d). The respective tophalf of the mold was created by inverting the cured silicone and Al filter, removing the
clay and spraying exposed surfaces with mold release (Smooth-Cast® Ease-Release, PA,
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USA). Fill and evacuation ports were modelled from clay and affixed to the Al filter. A
second batch of silicone elastomer mixture was poured to cover the exposed Al filter and
allowed to cure (Figure 3.2de). The tight fit of the co-registered two-part mold
(Figure 3.2f) would prevent leaking of the poured Er-infused resin casting mixture.
To cast the low-energy Er x-ray filter, erbium oxide (Er2O3, American Elements, CA,
USA) nanoparticles (nominal diameter ~ 50 nm) were incorporated within a 9-minute
pot-life two-part resin mixture (Smooth-Cast® 321, Smooth-On, PA, USA). To create an
effective Er-foil pathlength of 68 µm, 5.27 g of Er2O3 was mixed thoroughly with 30 mL
of Part B and placed in a vacuum chamber (~101.3 kPa) until all air bubbles had been
evacuated. An equal volume of Part A (30 mL) was carefully mixed with the Part B and
Er2O3 mixture for a total of 2.5 minutes. The resin mixture was placed back into the
vacuum chamber for an additional 2.5 minutes (achieving ~ 68 kPa). To minimize
introduction of air bubbles during casting, the resin mixture was poured as a slow and
thin continuous stream into the fill port of the silicone mold (Figure 3.2f). The Er-infused
resin was cured overnight before extraction and removal of excess resin (Figure 3.2g).
The cast low-energy Er x-ray filter resulted in a 49% reduction of photon flux.
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Figure 3.2: Process implemented to fabricate a custom silicone mold used to cast custom resin
x-ray filters. (a) Master machined aluminum (Al) filter. (b) Assembled box, comprised of
multiple acrylic pieces, to encompass the two-part silicone that is to be poured over the embedded
Al filter within a layer of sulphur-free clay. (c) Extracted silicone mold representing the bottomhalf of the silicone mold. Circle emphasizes one of the 7 registration keys that were used to
ensure accurate assembling of the silicone bottom- and top-half. (d) Silicone mold of the top-half.
Circle represents the corresponding registration key from (c). (e) Top-half of the silicone mold
flipped to demonstrate the fill and evacuation ports (arrows). (f) Assembled silicone mold. (g)
Fabricated custom x-ray filters, the erbium-impregnated resin casted low-energy filter (right) and
the copper foil wrapped around acrylic core high-energy filter (left).
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3.2.3

Dual-Energy Micro-Computed Tomography

All samples were scanned with our DECT protocols on a pre-clinical gantry-based conebeam micro-CT scanner (Vision 120, GE Healthcare, London, ON, CAN). The lowenergy scan parameters were 70 kVp, the additional Er-cast resin filter (as previously
described), and 50 mA. The high-energy was acquired at 90 kVp, with the previously
mentioned Cu filter, and 40 mA. Both low- and high-energy scans were acquired with 50
µm isotropic voxel spacings, 1200 projections at 0.3° increments over 360°, 10 frames
averaged per projection, and 16 ms per frame. The total time required for each energy
scan was approximately 1.5 hrs, which included the time required for gantry motion and
recording of image projections; thus, a complete DECT scan was ~3 hrs. Reconstructed
three-dimensional (3D) images were rebinned 2 × 2, resulting in 100 μm isotropic voxel
spacing. Images were rescaled into Hounsfield units (HU) using vials of water and air
within the field of view.

3.2.3.1.1

Image Co-Registration

Fiducial markers beads (1.6 mm polytetrafluoroethylene (PTFE), Teflon™, Figure 3.3b
circles) were embedded in a distributed pattern (Figure 3.3ab) throughout a custom
radiolucent polystyrene foam sample holder. Fiducial markers of PTFE were chosen as
they provided sufficient contrast (making them easily segmented) and introduced
minimal image artifacts. The centroid of a minimum of eight fiducial markers were used
to derive a transformation matrix using a least-square fitting method;28 wherein the highenergy image was rigidly transformed to the low-energy image with sub-voxel accuracy.
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Figure 3.3: Instrumentation implemented on the micro-CT scanner, which facilitated the
switching of x-ray filters and aided in image co-registration. (a) Individual pieces of the
automated filter-exchange mechanism: (i) linear actuator filter-exchanger; (ii) control box for
filter-exchange mechanism; (iii) clam shell which resides on the CT scan bed to support the x-ray
filters; (iv) custom Er and Cu x-ray filters mounted to an acrylic cylinder; and, (v) radiolucent
sample holder and sample. (b) Enhanced view of sample holder (a-v) to emphasize the many
embedded fiducial markers, three of which have been encircled. (c) The entire setup assembled
on our micro-CT scanner.
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DECT Automation
To increase sample throughput and reduce operator dependencies, a motorized filterexchange mechanism (Figure 3.3) was constructed to automate the DECT acquisition
process. The filter-exchange mechanism automatically switches x-ray filters within the
scanner bore, in between the low- and high-energy scans. Mounted on an acrylic cylinder
(with an OD and WT identical to the master Al filter), the custom Er and Cu x-ray filters
were actuated with a motor-driven lead screw (Figure 3.3ai) controlled by an embedded
micro-controller (Arduino Uno, Figure 3.3aii). The filter-exchange mechanism assembly
was secured on the micro-CT scan bed with a simple screw jack system.

3.2.4

Contrast Agent Preparation

The preparation of the Er-based ex vivo vascular perfusion contrast agent has been
previously described in Chapter 2;22 briefly, perfusion of a sample required the
formulation of a catalyzing curing agent and the Er-based suspension.
The curing agent and Er-based contrast agent were prepared prior to perfusion in
accordance to Chapter 2. The curing agent was comprised of 60% v/v dibutyl tin
dilaurate (DBT) and 40% v/v tetraethylorthosilicate (TEOS) mixed until a homogeneous
transparent pale-yellow colour was achieved. The Er-based contrast agent was comprised
of a two-part silicone elastomer (Microfil 132, FlowTech Inc, MA, USA) with uniformly
dispersed Er2O3 nanoparticles (nominal diameter 50 nm, Nanostructured and Amorphous
Materials, TX, USA). To create a volume of 30 mL, sufficient for a single rat hindlimb
perfusion, 4.0 g of Er2O3 (13.3 % w/v) was mixed within 8.73 ml of MV-132 and
17.47 ml of MV-Diluent and probe sonicated for a total of 35 minutes.22 The remaining
3.8 mL was comprised of the curing agent, as described above, added immediately prior
to perfusion.

3.2.5

Rat Hindlimb Perfusion

A custom catheter with sufficient flexibility was created to aid in its manipulation during
surgery and prevention of accidental vessel tearing upon insertion. The catheter was
comprised of a blunted 18 G (BD, NJ, USA) needle with 15 cm of polyethylene tubing
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(#1417011F, Fisher Scientific, NH, USA) and 10 cm silicone tubing tip (#60985-724,
VWR, PA, USA). To join the silicone and polyethylene tubing, the silicone tubing was
placed in diethyl ether (Sigma Aldrich, MI, USA) for ~10 s, causing the tubing to swell
and ease its placement over the polyethylene tubing. A bevel was introduced on the tip of
the silicone tubing.
The Animal Use Subcommittee at the University of Western Ontario approved all animal
experiments (protocol #2015-018). Ten male wild-type Sprague-Dawley rats (Harlan,
Indianapolis, IN, USA) were anesthetized and maintained with 3% isoflurane (in 2% O2)
isoflurane (Sandoz, QC, CAN). Five minutes prior to surgery, a jugular injection of
500 μl heparin (to prevent blot clotting) was administered. An incision along the
abdomen was made, and organs were parted till the aorta and inferior vena cava (IVC)
were visualized. The parietal peritoneum covering the IVC and aorta was carefully
separated from the underlying vessels using gauze. Two lengths of silk thread (~ 8 cm)
were passed in between the separated aorta and IVC. One length of thread was used to tie
off the aorta below the renal artery. Downstream of the tied-off aorta, a small incision
was made in the aorta. The custom catheter (as described above) was inserted and
maneuvered until the tip of the catheter was ~ 1- 2 cm above the aortic bifurcation. The
second thread was gently tied off around the aorta and catheter, holding the catheter in
place. The IVC was severed to allow for circulatory drainage. Hindlimbs were flushed
with ~250 mL of 0.4% heparinized saline prior to perfusion of the Er-based contrast
agent.
3.8 mL of the prepared curing agent was added to the Er-suspension and vortexed
continuously for 8 minutes. The mixture was injected into an IV bag and suspended
175 cm above the animal, equivalent to 129 mm Hg. The contrast agent was perfused
until cured (i.e. ~37 minutes post addition of curing agent). Rat hindlimbs were fixed in
10% formalin for at least 2 weeks prior to the excision of the left hindlimb, its embedding
within agar, and scanning with the previously outlined DECT protocols.
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3.2.6

Image Processing

To assess the homogeneity (i.e. uniform distribution of Er2O3 nanoparticles) of the cast
Er-embedded resin filter we scanned the entire Er-filter at 90 kVp, 40 mA, 900 views,
0.4º increments over 360º, 16 ms exposure, and total scan time of 5 minutes. The
resulting volume was rebinned 2 × 2 for a final resolution of 100 µm. The mean CT
values from ten randomly placed 300 × 300 × 300 µm regions-of-interest (ROIs)
(MicroView, v2.2.RC5, GE HealthCare, London, ON, CAN) throughout the scanned Erfilter were recorded and analyzed with a t-test, and significance was achieved if p < 0.05.
Decomposition of DECT images were performed via matrix factorization, as previously
outlined by Granton et al., 2008;29 and a more detailed explanation can be found in
Appendix C. However, briefly, the decomposition required six values, represented by the
mean HU value of pure soft-tissue, bone, and vessel from both low- and high-energy
scans. These values were obtained from 500 × 500 × 500 µm ROIs (MicroView) within
the bicep femoris region (soft tissue), cortical bone (bone), and the femoral artery
(vessel). The generated decomposed volumes represented quantitative maps of each
individual component, with voxel values (0 – 10,000 arbitrary units) representing the
volume fraction (0 – 100%, respectively) or the percent contribution of the decomposed
material within each individual voxel; the remaining percentages were comprised of a
mixture of the two remaining components. Note that using this approach, the volume
fractions of the three basis function materials (i.e. soft tissue, bone, and vessel) are
constrained to sum to 100%.
Quantitative evaluation on the accuracy of DECT decomposition accuracies was
performed on the perfused 10 rats by quantifying the number and distribution of
misclassified voxels within each decomposed volume (i.e. soft tissue, bone, and vessel).
To quantify misclassified voxels, the coordinates of ROIs (500 × 500 × 500 µm,
MicroView) within known areas of soft tissue (i.e. bicep femoris), bone (i.e. cortical
bone), and vessel (i.e. femoral artery) were recorded. The three recorded ROIs were
transposed within each decomposed volume of soft tissue, bone, and vessel. Mean values
from each ROI within each decomposed component were recorded and averaged over the
analyzed 10 samples. The sum of each tissue ROI across all decomposed volumes will
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equal 10,000 arbitrary units or 100% (e.g. the sum of the mean values from femoral
artery ROI transposed into the soft tissue, bone, and vessel decomposed volume will be
10,000 arbitrary units). Therefore, after normalizing the recorded values from all 10
samples, we can provide the percent of voxels that have been misclassified as another
tissue.
All statistical analysis was performed using Prism (GraphPad, v7.03, La Jolla, CA, USA).
A statistical significance was achieved if p < 0.05.
The use of 3D visualization software (VGStudio Max 2.0, Heidelberg, Germany)
provided further visual enhancements, such as colorization and visual interactions
between individual components.

3.3 Results and Discussion
3.3.1

DECT Design and Implementation on a Pre-Clinical MicroCT Scanner

In this study, we have designed and implemented custom x-ray filtration, an automated
filter-exchange mechanism, and fiducial marker-based image co-registration to
successfully decompose – with high accuracy – DECT-acquired images from a preclinical gantry-based cone-beam micro-CT scanner.
Using simple silicone casting techniques, we created a silicone mold that facilitated the
fabrication of an inexpensive and homogenous custom annular cylindrical Erimpregnated resin x-ray filter (Figure 2.2g). Excluding material costs for the production
of the silicone mold (~$50 for the stock Al and silicone), the cost of materials to cast a
single Er x-ray filter was ~$6, significantly cheaper than any Er-foil counterpart. The
homogeneity test revealed a statistical significant, but vanishingly small (given the noise
of ± 60 HU), difference of p < 0.001. However, the overall mean and standard deviation
of 2753 ± 29 HU suggested a homogeneously cast Er x-ray filter.
The constructed motorized filter-exchange mechanism (Figure 3.3ac) successfully
automated the acquisition of DECT images. This eliminated the need for operator-
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dependent filter switches and possible operator errors (i.e. incorrect filter choice and
inadvertent sample motion)
Easily segmented fiducial markers (Figure 3.3b) aided the semi-autonomous, sub-voxel
image co-registration, where operator intervention was required only to choose a seedpoint for the automated centroid calculation and co-registration. Together, the automated
DECT acquisition and image co-registration provide a nearly automated work-flow for
accurate DECT decompositions (as shown below).

3.3.2

DECT Results

The six values collected from ROIs of pure soft tissue, bone, and contrast-enhanced
vessel are summarized in Table 3.1. Implementing the previously described matrix
factorization,5 these six values facilitated the DECT decomposition of an Er-perfused rat
hindlimb into distinctly separate and quantitative 3D volumes of soft-tissue, bone
(Figure 3.4c), and perfused vasculature (Figure 3.4d).

Soft Tissue

Bone

Contrast-Enhanced Vasculature

(HU)

(HU)

(HU)

Low Energy

37

2743

1659

High Energy

0

1909

2059

Table 3.1: Mean values from ROIs drawn within known pure regions of soft tissue, bone, and Erperfused vasculature. The represented six numbers were chosen as input parameters for the
automated decomposition algorithms.
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Figure 3.4: Dual-energy computed tomography (DECT) results of an Er-perfused rat hindlimb.
Displayed are the low- and high-energy images acquired with the previously outlined DECT
protocols and implemented automated filter-exchange mechanism and custom x-ray filtration.
The acquired (a) low- and (b) high-energy images are decomposed automatically into their
respective (c) bone- and (d) vessel-only components. The highly-accurate decomposition of bone
and vessels facilitated the visualization of vessels within the cortical bone, in addition to the
highly-vascularized sheets lining the outside and inside of each long bone, periosteum and
endosteum, respectively. The ability to visualize these vessels manifests as femur- and tibia-like
structures in the vessel-only image. Note the absence of the bone-mimicking calibrator from the
vasculature image, emphasizing the success of the DECT decomposition.
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The DECT decomposition yielded accuracies of 99.18%, 98.45%, and 99.78% in the soft
tissue, bone, and vessel volumes, respectively (Table 3.2), as quantified from ten
perfused rats. The visual representation of the amount and composition of misclassified
voxels within each decomposed volume is illustrated within Figure 3.5.

Soft Tissue
Decomposed
Volumes

Known Pure Components
Soft Tissue (%)
Bone (%)
Vessel (%)
99.18 ± 0.44
0.26 ± 0.64
0.01 ± 0.03

Bone

0.18 ± 0.10

98.45 ± 1.40

0.20 ± 0.38

Vessel

0.66 ± 0.45

1.29 ± 1.03

99.78 ± 0.42

Table 3.2: DECT decomposition quantitative assessment. 500 × 500 × 500 µm ROIs were placed
within known areas of soft tissue, bone, and vessels in each decomposed volume. The mean
values of each ROI were recorded and normalized to 100 % within each individually decomposed
volume.

Figure 3.5: Graph depicting the percent of misclassified voxels after automatic DECT
decomposition. Within each decomposed volume, misclassified voxels are comprised of the
remaining two components.
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Isolated visualization of the soft tissue, bone, and vessels is achieved via DECT
decompositions. To image interactions between individual components, the decomposed
data can be processed with 3D visualization software. In our case, the addition of colour
to vessels (red) and bone (white) provided enhanced visualization to emphasize the
vasculature surrounding and traversing within bone (Figure 3.6).

Figure 3.6: Dual-energy computed tomography (DECT) results after processed with 3D
visualization software to emphasize the interactions between decomposed components – vessels
(red) and bone (white). (a) Overall view of the vasculature outside and on the surface of the
perfused rat hindlimb. (b) An internal cross-sectional view of the area outlined in yellow from
(a). Note the highly vascularized internal nature of bone. Yellow arrows denote the primary
nutrient vessels of the femur and tibia.
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3.3.3

Importance of X-Ray Filtration and Image Co-Registration

Integration and implementation of multiple techniques (i.e. custom x-ray filtration,
automated filter-exchange mechanism, fiducial markers, and image co-registration) are
required for the optimal performance of DECT on pre-clinical gantry-based cone-beam
micro-CT scanners. Any deficiency or absence in any of these techniques (i.e. spectral
shaping and image co-registration) will result in non-ideal DECT decompositions. We
demonstrated the importance of spectral shaping (via x-ray filtration) and image coregistration by performing the following experiments and data re-analysis.
Five Er-perfused rat hindlimbs were re-scanned (with the previously outlined DECT
protocols) in the absence of customized x-ray filtration. The resulting sub-optimal
spectral shaping and large spectral overlap are visualized in Figure 3.1 (top panel).
Acquired low- and high-energy scans were co-registered and decomposed with a new set
of six CT intensity values: low-energy soft tissue (45), bone (2930), vessel (2647), and
high-energy soft tissue (45), bone (2572) and vessel (2768). The DECT decomposition
resulted in a large number of misclassified voxels between decomposed volumes
(Figure 3.7), visualized as “bleeding” between components. Visually, the perfused
vasculature (Figure 3.7d) appears to have been decomposed properly; however,
quantitative analysis revealed that only 76.23% of the vessels had been classified
correctly (Table 3.3), with the majority misclassified as bone (Figure 3.7b). The
remaining percentages (23.77%) and compositions of misclassified voxels are presented
in Table 3.3 and visualized within Figure 3.8.
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Figure 3.7: Dual-energy computed tomography (DECT) results of the Er-perfused rat hindlimb if
no spectral shaping was implemented during the collection of the dual-energy images. Similar to
results presented in Figure 3.4, DECT-acquired (a) low- and (b) high-energy images were
acquired with the previously outlined DECT protocol, in the absence of the fabricated custom
low- and high-energy x-ray filtration, co-registered images, and a separate set of six values (as
without x-ray filtration, CT values of pure soft tissue, bone, and vessel will be different than in
the presence of x-ray filtration) and were utilized for decomposition. Results of the
decomposition are displayed in (c) bone- and (d) vessel-only image. Note the misclassified vessel
voxels (i.e. “bleeding”) within the bone image.
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Soft Tissue
Decomposed
Volumes

Known Pure Components
Soft Tissue (%)
Bone (%)
Vessel (%)
97.33 ± 0.54
0.36 ± 0.42
6.79 ± 10.53

Bone

2.08 ± 0.81

99.37± 0.59

16.96 ± 9.66

Vessel

0.54 ± 0.61

0.27 ± 0.59

76.23 ± 12.61

Table 3.3: DECT decomposition quantitative assessment in the absence of proper x-ray filtration.
500 × 500 × 500 µm ROIs were placed within known areas of soft tissue, bone, and vessels in
each decomposed volume. The mean values of each ROI were recorded and normalized to 100 %
within each individually decomposed volume.

Figure 3.8: Graph depicting the percent of misclassified voxels, from Table 3.3, after automatic
DECT decomposition. Within each decomposed volume, misclassified voxels are comprised of
the remaining two components.
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To establish the importance of image co-registration, data collected for Figure 3.4 was
re-analyzed without co-registration prior to DECT decomposition. The decomposition
results (Figure 3.9) appeared similar (i.e. misclassified voxels, “bleeding”) to those that
have been acquired without proper spectral separation (Figure 3.7); however, the
“bleeding” was more apparent across all decomposed volumes. Clearly, the sequentially
acquired low- and high-energy volume images are not inherently co-registered at the subvoxel level; this is likely due to a combination of small (and unavoidable) variations in
positioning of the scanner bed and gantry between scans.
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Figure 3.9: Dual-energy computed tomography (DECT) results of the same Er-perfused rat
hindlimb if the low- and high-energy images were not co-registered prior to decomposition.
Similar to results presented in Figure 3.4, DECT-acquired (a) low- and (b) high-energy images
were acquired with the previously outlined DECT protocols and custom x-ray filtration; however,
the fiducial markers (present on the periphery of each image) were not utilizes for image coregistration. Decomposition with these images resulted in the displayed (c) bone- and (d) vesselonly image. Mis-registration results in the misclassification of an objects’ non-overlapping
boundaries. As maximum intensity projections (MIP) are presented here, entire vessels and bone
will appear to have been misclassified when this is in fact incorrect, and only the boundaries of
these tissues have been misclassified. Note the large amount of “bleeding” of bone (and bone
mimicking calibrator) within the vessel image, and vice versa.
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Thus, it is apparent both visually (Figures 3.7 and 3.9) and quantitatively (Table 3.3) that
both spectral separation and image co-registration are necessary for the proper collection
and optimal decomposition of DECT-acquired images.

3.3.4

Limitations

While our work has overcome the challenges of spectral separation and image
co-registration – required for the optimal implementation of DECT on pre-clinical conebeam micro-CT scanners – several optimizations and limitations remain. The addition of
our customized x-ray filtration resulted in > 98% decomposition (Table 3.2 and
Figure 3.5). However, optimizations of the DECT acquisition process may be achieved
with different filter concentrations. As an example, a reduction in x-ray filtration may
yield similar decomposition results and the concurrent increase in CNR may allow for
reduced scan times.
A limitation within our study is the limited performance of DECT to a single field-ofview (FOV), as the constructed automated filter-exchange mechanism can only actuate
the filters between two hard-coded positions. However, modifications to the filterexchange mechanism to actuate the sample holder or allow further travel distances of the
x-ray filters would facilitate DECT of whole small animals.
An additional limitation is that our perfusion procedure precludes in vivo studies;
however, there is currently research investigating an Er-based in vivo vascular perfusion
contrast agent.30 These future studies would also entail researching suitable DECT x-ray
filtration compatible with the vascular contrast agent, in addition to balancing an
acceptable x-ray dose for in vivo studies.

3.4 Conclusion
In this study, our implementation of DECT on a conventional pre-clinical laboratory
cone-beam micro-CT scanner allowed for the automatic decomposition of Er-perfused rat
hindlimbs into separate, distinct, and quantitative images of soft-tissue, bone, and
perfused vasculature. This was achieved by sequential acquisition with two differential
x-ray spectra, incorporating sub-voxel volumetric image co-registration between scans.
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These scans were acquired with custom-fabricated x-ray filtration, an automated filterexchange mechanism, and embedded fiducial markers that allowed for image coregistration using a rigid matrix transformation. The automated decomposition into
specific tissue components was accurate to within 2%, facilitating quantitative analysis of
specimen composition within 100 µm cubed voxels (i.e. 1 nL volume elements). The
additional required hardware and software modifications did not interfere with the normal
operation of a conventional commercial micro-CT scanner.
As part of this novel implementation of DECT, this study presented a methodology for
the fabrication of custom x-ray filters, optimized for the spectral shaping associated with
an Er-based contrast agent. In the future, this fabrication technique can be modified to
create user-specified custom (i.e. shape, elemental composition, and concentration) resinembedded x-ray filters of any element present in nanoparticulate powders. This range of
customization would facilitate the application of DECT to take advantage of other
exogenous contrast agents, or endogenous contrast within the specimen.
The methodology presented here will have applications in a range of biomedical research,
including the study of cardiovascular disease, respiratory conditions, cancer, and
osteoarthritis. Our approach for optimal spectral shaping using customized filters is also
applicable

in

non-biomedical

research,

including

earth-science

applications

(e.g. geological specimens and meteorite analysis), archaeological studies, and nondestructive testing of 3D-printed objects. Additionally, the techniques that we have
described within our study are applicable to a large installed base of micro-CT scanning
systems, as well as conventional multi-slice CT scanners for research applications.
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Chapter 4

4

Studying Femoral- and Tibial-Subchondral Bone and
Vascular Changes Using Dual-Energy Micro-Computed
Tomography in a Surgically-Induced Rat Hindlimb
Model of Osteoarthritis

4.1 Introduction
Osteoarthritis, OA, is a chronic debilitating joint disease that affects millions of
individuals.1-3 This joint disease affects multiple joints (e.g.. hand,4 hip,5 knee,6 and
spine7) and is the result of cartilage and bone degeneration, presenting symptomatically
as joint stiffening and pain. Presently, no drugs or treatments can halt or reverse the bone
and cartilage degeneration resulting from the progression of OA.8 The absence of
effective OA-treatments are attributed to OA’s complex and multifactorial nature; factors
such as age,9,10 pre-existing injuries,11-13 diabetes,14-16 and genetic predisposition17,18 have
all been shown to contribute to the development of OA. One interesting hypothesis – and
of increasing interest – revolves around the role of microvessels within subchondral bone
of affected joints.19-24
Microvessels are essential for the healthy maintenance of joint-associated bone and
cartilage; these vessels facilitate the transportation of nutrients, oxygen, and
inflammatory molecules to the joint, in addition to removal of cellular waste products.2527

Cartilage is an avascular tissue (i.e. does not contain any blood vessels); thus, all of its

resources must be provided by the highly-vascularized neighboring synovium28 and
subchondral bone.29,30 With cartilage’s vital dependency on neighbouring tissues for its
healthy maintenance, it has been hypothesized19,21,31 that OA may stem from changes to
the delicate microvascular homeostasis of naïve joints, negatively impacting the
development and physiology of the local bone and cartilage environment. A decrease in
blood vessel density or competency may result in diminished oxygen and nutrient supply
to the joint, and a buildup of waste products. Combined, these effects may trigger an
inflammatory response from the synovium or subchondral bone and cause cartilage
degeneration.19,20,32 Alternatively, an increase in blood vessel density may prompt
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angiogenic factors to initiate the vascular invasion of cartilage – an otherwise avascular
environment – triggering its self-degradation.33,34 While the microvessels encapsulating
the synovial joint are known to be responsible for the majority of cartilage’s nutrients and
oxygen,28 there has been increasing interest in the role of subchondral bone microvessels
in the maintenance29 and degeneration20 of cartilage. Of particular interest are the distal
femoral epiphysis and proximal tibial epiphysis, due to their proximity to the
cartilaginous surfaces of the joint. Thus, simultaneously studying changes in subchondral
bone and microvessel densities throughout the course of OA may provide insight into
whether a decrease or increase in microvessels is associated with OA.
The quantitative pre-clinical study and characterization of blood vessels within intact
bone has proven challenging due to difficulties in imaging microvessels. Three properties
of microvessels have impeded the simple segmentation of vessels from surrounding bone:
(1) their small size (i.e. < 10 µm, capillaries); (2) lack of inherent contrast against
surrounding tissue; and (3) proximity to dense bony structures. Currently, histology
remains the gold standard for the study of microvessels; unfortunately, histology of joints
requires the decalcification of bone prior to histological sectioning, an inherently
destructive process, resulting in the loss of bone information. Alternatively, micro-CT is
routinely used for the non-destructive imaging of bone;35 however, visualization of blood
vessels requires the addition of an exogenous contrast agent.
In Chapters 2 and 3, we characterized a highly x-ray attenuating Er-based micro-CT
ex vivo vascular perfusion contrast agent36 and its combination with optimized dualenergy computed tomography (DECT) on a pre-clinical, gantry-based, cone-beam microCT scanner,37 respectively. Our proposed technique facilitated the automated acquisition
of DECT volume images of Er-perfused samples and the subsequent volume-image
decomposition, resulting in individually-segmented, co-registered, quantitative volumes
of soft tissue, subchondral bone and microvessel density.37 Implementing this previously
described technique with an animal model of OA will allow for the simultaneous study of
OA-associated microvessel and subchondral bone changes.
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Previous research in rats has shown that the combination of an anterior cruciate ligament
transection (ACLX) and partial medial meniscectomy (PMM) to cause joint instability,
bone-on-bone grinding during joint loading, and the eventual cartilage loss associated
with OA.38-40 Additionally, ACLX + PMM mimics the subtle and early subchondral bone
changes observed within human pathogenesis of OA.38 Therefore, in this study, we utilize
the techniques developed in Chapters 2 and 3 to quantify the subchondral bone and
microvessel density changes within the distal femoral epiphysis and proximal tibial
epiphysis of rats that have undergone the ACLX + PMM OA-inducing surgery. Our
experimental design extended prior-to and 8-weeks post-operatively, allowing for the
simultaneous visualization, characterization, and quantification of subchondral bone and
microvessels throughout the initiation and progression of OA.

4.2 Materials and Methods
4.2.1

Animal Model

All animal manipulations in the following study were approved by the Animal Use
Subcommittee of Western University (protocol #2015-018). Sprague-Dawley rats (N =
54, Harlan Laboratories, IN, USA) of 300 - 325g (~3 months of age) were used
throughout the experiment. Six rats were perfused (as described below) for the 0-week
controls, the remaining N = 48 were divided in half for the ACLX + PMM and sham
surgery groups. Within each surgery group, animals were further sub-divided (N = 6) for
each experimental time point: T = 0 (pre-operative), 1, 2, 4, and 8 weeks postoperatively. Previous work with this animal model of OA encompassed the 2, 4, and 8
weeks post-operatively timepoints; however, we included a 1-week post-operative
timepoint as we were interested in observing possible early changes to the soft tissue,
bone, and microvessels. Animals were monitored daily and weighed prior to surgery and
perfusion. All animals were housed in standard cages and permitted free activity with
food and water provided ad libitum.

4.2.1.1

Sham and OA-Induced Surgeries

Prior to surgery, animals were anesthetized and maintained with 4% isoflurane (Baxter,
ON, CAN) and 2 ml/min O2. All surgeries were performed solely on the right hindlimb
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(ipsilateral), allowing the left (contralateral) hindlimb to serve as an internal control. For
both OA-induced and sham surgeries, a parapatellar incision was made on the medial
aspect of the joint, anterior to the medial collateral ligament. Rats that underwent the OAinduced surgery had the anterior cruciate ligament transected (ACLX) and a portion of
the medial meniscus removed (PMM). Both sham and ACLX + PMM surgeries had the
incisions closed in two layers with interrupted sutures using absorbable 5-0 Vicryl sutures
(Ethicon, Johnson & Johnson Medical Products, ON, CAN), and the skin was closed with
subcuticular sutures using 4-0 Vicryl (Ethicon, Johnson & Johnson Medical Products,
ON, CAN).
All animals were given antibiotics and analgesics pre- and post-operatively. Antibiotics
(17.8 mg/kg Ampicillin, Novopharm®, ON, CAN) were administered intramuscularly. In
compliance with standard operating protocols set by the Animal Care and Use Committee
at Western University, the analgesic buprenorphine (0.05 mg/kg, Vetergesic Multidose,
Champion Alstoe Animal Health, ON, CAN) was administered subcutaneously every
~10 hours over 48 hrs post-operatively.

4.2.2

Er-Based Contrast Agent and Curing Agent Preparation

Preparation of the Er-based suspension has been previously outlined in Chapter 2.36
Briefly, perfusion required the combination of two components: an Er-based suspension
and a curing agent.
The Er-based vascular contrast agent (described in Chapter 2) is comprised of erbium
oxide nanoparticles (Er2O3 NPs, Nanostructured and Amorphous Materials, TX, USA)
suspended within a two-part clear silicone elastomer (Microfil MV-132, FlowTech Inc.,
MA, USA). The Er-based contrast agent was prepared in 30 mL batches, a sufficient
volume for rat hindlimb perfusions. The Er-suspension was comprised of 4.0 g of mortar
and pestle ground uncoated Er2O3 NPs mixed into MV-Diluent (17.47 mL) and MV-132
(8.73 mL) in a 2:1, respectively. The remaining 3.8 mL was comprised of the homemade
curing agent, as described below, added immediately prior to perfusion. To ensure the
homogeneous distribution of Er2O3 NPs within the silicone elastomer, the suspension was
probe sonicated (Branson Digital Sonifier 450D with 13 mm tapped horn, Crystal
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Electronics, ON, CAN) for a total of 35 minutes with 25% amplitude and a duty cycle of
30 s ON followed by 10 s OFF. The contrast agent was prepared at least an hour in
advance and decanted just prior to use, to remove the larger settled aggregates.
To ensure the consistent curing of our Er-based suspension, the curing agent was made
in-house and was comprised of 40% (w/w) dibutyltin dilaurate (Sigma Aldrich, MI,
USA) and 60% (w/w) tetraethyl orthosilicate (Sigma Aldrich, MI, USA) mixed with a
magnetic stirrer until a homogeneous transparent pale-yellow mixture was achieved.

4.2.3

Animal Perfusion

The perfusion of animals and fabrication of a custom catheter have been previously
described in Chapter 3.37 In brief, at the time of perfusion, animals were weighed,
anesthetized and maintained on 4% isoflurane (Baxter, ON, CAN) with 2 mL/min O2. A
jugular injection of heparin (500 µL, Sandoz, QC, CAN) was administered to prevent
blood clotting. Heparin circulated for 5 minutes prior to making a midline incision to
expose the abdominal organs. The organs were displaced to clearly reveal the aorta and
inferior vena cava (IVC). Gauze was then used to carefully separate the membrane
covering the aorta and IVC. Two lengths of braided silk thread (~ 10 cm, Ethicon,
Johnson & Johnson Medical Products, ON, CAN) were passed between the aorta and
IVC. One length of thread was used to tie off the aorta, below the renal arteries. Finetipped forceps were inserted into a cut made perpendicular to the aorta; spreading the
forceps allowed the insertion of the custom catheter. The catheter tip, maneuvered until
~1-2 cm upstream of the aortic bifurcation, was held securely in place with the tied-off
second length of thread. The IVC was cut to allow for circulatory drainage, as the animal
was exsanguinated with ~ 250 mL of 2% heparinized saline prior to perfusion of the Erbased vascular contrast agent.
Just prior to contrast agent perfusion, 3.8 mL of the homemade curing agent was added to
the Er-based suspension and vortexed (VWR® Fixed Speed Vortex Mixer, PA, USA)
continuously for 8 minutes. The entire mixture was injected into an empty saline bag and
hung 175 cm above the animal, providing an equivalent pressure of 129 mmHg. The
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contrast agent was perfused until cured, ~ 37 minutes post-addition of curing agent. The
rat hindlimb region was fixed in 10% formalin for at least 2 weeks prior to DECT scans.
Following fixation, hindlimbs were dislocated at the femoral head, excised, and placed
within 50 mL tubes with 10% formalin. After another week in formalin (to ensure
complete fixation throughout the entire hindlimb), samples were stored in 70% ethanol
until DECT-scanned.

4.2.4

Dual-Energy Micro-CT Scanning

Details regarding the entire dual-energy micro-CT (DECT) procedure (i.e. acquisition,
image co-registration, and image analysis) have been previously described in Chapter 3.37
Briefly, post-mortem DECT was performed on a pre-clinical, gantry-based, cone-beam,
micro-CT scanner (GE eXplore Vision120, GE HealthCare, ON, CAN). High-energy
scans were acquired at 90 kVp, 40 mA, with an additional annular cylindrical Cu x-ray
filter of total pathlength 0.48 mm. Low-energy scans were collected at 70 kVp, 50 mA,
using a custom fabricated Er-embedded resin x-ray filter with effective pathlength of
0.064 mm. Each energy scan was collected over 1200 projections, at 0.3° increments over
360°, 16 ms per view acquisition time, and an average of 10 acquisitions per view
projection. Scan time at each energy was ~ 1. 5 hrs; thus, the total time required for a
DECT scan of a single sample was approximately 3 hrs. All data were collected with an
isotropic voxel spacing of 50 × 50 × 50 µm and subsequently rebinned 2 × 2, resulting in
full three-dimensional (3D) micro-CT volumes of 100 × 100 × 100 µm isotropic voxel
spacing. The reconstructed micro-CT volumes were calibrated into Hounsfield (HU)
units wherein the CT value of an embedded water and air calibrator set to 0 and -1000
HU, respectively.
Fiducial marker beads (Teflon®, polytetrafluoroethylene (PTFE), Product Components
Corporation, Martinez, CA, USA) within the sample holder were used to achieve subvoxel image co-registration between the high- and low-energy acquired micro-CT
volumes. Decomposition of the DECT-acquired images was performed through matrix
factorization,41 and resulted in individually segmented and quantitative volumes of soft
tissue, bone, and vessel. Within each decomposed volume, signal intensity values were
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scaled such that integer grey-scale voxel values (0 – 10,000) represented the voxel
volume fraction (0 – 100%) of the respective component.

4.2.4.1

Partial Volume Effect (PVE)

Distinguishing between individual microvessels (i.e. capillaries, < 10 µm) is not possible
with DECT-acquired images with (100 µm)3 voxels due to partial volume effects (PVE).
However, previous research42-44 has suggested that DECT may be partially resistant to
PVE, as DECT may still allow for the accurate detection and quantification of
microvessel densities over varying spatial resolutions. To quantitatively evaluate PVE on
DECT decompositions, we compared the same volume-of-interest (VOI) among five rat
hindlimbs that were DECT scanned with 33 µm isotropic voxel spacing and subsequently
rebinned 2 × 2, 3 × 3, and 4 × 4, resulting in isotropic voxel spacings of 66, 99, and 132
µm, respectively.
For this study of partial volume effects, DECT scans were acquired on a rotating-stage
specimen scanner (GE Locus SP, GE Healthcare, London, ON, CAN). The high-energy
image was acquired at 90 kVp, 90 µA, and with additional filtration of 0.254 mm Cu and
0.254 mm Al. The low-energy scans were performed at 64 kVp, 125 µA, and an
additional 0.075 mm Er-foil x-ray filter. Both x-ray energy scans were collected over 720
projections, at 0.5º increments over 360º, 1600 ms exposure time per view, and an
average of 20 views per projection. Images were reconstructed with isotropic voxel
spacing of 33 × 33 × 33 µm subsequently rebinned to 66, 99, and 132 µm (as previously
stated). Individual energy scans were approximately 8 hr each, totaling ~ 16 hrs for a
DECT scan of a single sample. Reconstructed volumes were calibrated into HU units
using embedded air and water calibrators prior to DECT decomposition.

4.2.5
4.2.5.1

Data Analysis
DECT and PVE Analysis

Studying the subchondral bone and microvessel density within the distal femoral
epiphysis and proximal tibial epiphysis required the generation of custom volumes-ofinterest (VOI). Within each high-energy volume, 2D contours were generated by an
operator (MicroView v2.12, GE HealthCare, ON, CAN) by following the cortical shell
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and growth plate (Figure 4.1A). This contouring process was repeated every 200 μm,
until the entire joint had been encompassed. Interpolation between the individual 2D
contours resulted in a 3D VOI (Figure 4.1B). The derived VOI was transposed within
each inherently co-registered decomposed volume (soft tissue, bone, and vessel,
Figure 4.1C and D), and mean values were recorded from both the operated and nonoperated hindlimbs from all N = 54 rats.
Previous research45 has demonstrated that inter-animal variability can be a confounding
factor when analyzing statistical vascular differences between animals of differing
surgery groups and timepoints. To overcome the challenge of inter-animal variability, at
each timepoint the voxel volume fraction results of soft tissue, subchondral bone, and
vascular density measurements have been presented as a comparison between the
ipsilateral (operated) and respective contralateral (non-operated, i.e. control) hindlimbs.
Using the mean value acquired from a 500 × 500 × 500 µm ROI within the femoral
artery, a paired t-test was performed to ensure the non-significant differences in contrast
enhancement between the ipsilateral and contralateral hindlimbs of each rat. Using the
same data, a linear regression analysis was performed to examine whether consistent
contrast enhancement was achieved across the entire 8 – week post-operative timeframe.
This evaluation of contrast enhancement within a large feeding vessel was performed as
part of routine quality assurance, to verify that the perfusion and scanning procedure was
stable over the course of the study.
To evaluate the effects of PVE on DECT, the voxel volume fractions of identical VOIs
(as described above) were compared across varying voxel spacings (i.e. 33, 66, 99, and
132 µm). The same six CT numbers required for DECT decomposition (i.e. mean values
of soft tissue, bone, and vessel at both low- and high-energy) were used for each rebinned
volume. To ensure that the same custom VOI, generated from the 33 µm native
resolution volume, was applied to each subsequent rebinned volume, interpolation of all
rebinned volumes to the native isotropic voxel spacing of 33 µm was performed. The
mean values of custom VOIs transposed within bone- and vessel-only DECT
decomposed images were collected from three rat hindlimbs, normalized, and analyzed
within Prism (Graphpad v7.03, La Jolla, CA, USA).
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Figure 4.1: Multi-planar reformatted images of a DECT-scanned perfused rat hindlimb. (A)
Two-dimensional (2D) contour around the distal femoral epiphysis, drawn within the
DECT-acquired high-energy x-ray image. (B) 3D volume-of-interest (VOI) generated from the
extrapolation of 2D contours drawn manually every 200 µm throughout the joint. The 3D VOI
was then transposed within the co-registered, DECT-decomposed (C) bone-only and (D) vesselonly volumes. Mean values within each 3D VOI were collected and recorded.
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4.2.5.2

Histological Analysis

The investigation of OA-related physiological markers (i.e. lesions, and cartilage loss)
was performed through the histological examination of two perfused rat knee joints. To
prepare samples for histological analysis, perfused hindlimbs were first decalcified prior
to serial sectioning and staining.
The process of rat hindlimb decalcification encompassed a 5-day long procedure. On day
1, soft tissue and muscle surrounding the knee joint were trimmed and removed (with
care taken near the joint capsule) to aid penetration of the decalcification solution.
Trimmed hindlimbs were submerged within ~35 mL of decalcifying solution (Formical2000, Fisher Scientific, NH, USA) and placed on a rocking platform overnight. On day 2,
tissue and bone were further trimmed to within ~ 1 –2 cm above and below the joint
capsule. Samples were placed back in the same decalcification solution and rocked
overnight. On day 3, joints were bisected along the medial aspect of the tibia. To
facilitate the bisection and provide clean, straight, and consistent cuts, a custom
easy-to-use guillotine (Figure 4.2) was constructed. Bisected sections were submerged
within fresh ~35 mL decalcification solution and rocked for a day (i.e. day 4). On day 5,
samples were rinsed twice in distilled water for 5 minutes each and stored within 70%
ethanol at 4º C until histological processing.
Decalcified and bisected joints were dehydrated through a series of increasing alcohol
concentrations, in preparation for paraffin embedding. Histological sectioning of
embedded samples involved the collection of five 6 µm serial sections followed by a
100 µm tissue trim, until a total of ~ 120 µm of tissue had been accumulated. Selected
sections were stained with Toluidine blue to assess the presence of OA. Toluidine blue
preferentially stains proteoglycans and glycosaminoglycans (i.e. major components of
cartilage), and the intensity of the Toluidine blue staining reflects cartilage health (i.e.
weak Toluidine blue stains implies reduced proteoglycans and glycosaminoglycans or
degraded cartilage health and vice versa).46
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Figure 4.2: Constructed custom rat knee bisector. (A) Arbor press with a modified insert (black
arrows) that can accommodate and hold razor blades firmly via a contoured clam shell design. (B)
Assembled knee bisector. Cutting surface (polyoxymethylene, Delrin®) is removable and
customizable (i.e. implementation of customized anatomical indentations).

4.2.5.3

Statistical Analysis

All image analysis was performed with MicroView software (v2.12, GE Healthcare,
London, ON, CAN). Subsequent statistical analysis was done using Prism (Graphpad
v7.03, La Jolla, CA, USA), and statistical significance was achieved if p < 0.05.
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4.3 Results and Discussion
The successful complete perfusion of rat hindlimbs and selected ROIs (i.e. distal femoral
epiphysis and proximal tibial epiphysis) was demonstrated via the contrast enhanced
visualization of the epiphyseal (Figure 4.3A and B), metaphyseal (Figure 4.3C and D)
and primary nutrient arteries of long bones (Figure 4.3C and D). The previously
mentioned vessels represented the main blood supplies for the distal femoral epiphysis
and proximal tibial epiphysis. Within our study, all N = 56 rats exhibited contrast
enhanced epiphyseal, metaphyseal and primary nutrient arteries. Results of a paired t-test
between the ipsilateral and contralateral hindlimbs within each rat, to evaluate uniformity
of perfusion within each rat, showed no significant differences (p = 0.9275, Figure 4.4).
With no statistical different between ipsilateral and contralateral hindlimbs, values at
each time-point were averaged prior to linear regression analysis. Results of this analysis
revealed a non-statistically significant deviation from a slope of zero (p = 0.0828,
Figure 4.4).
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Figure 4.3: Maximum intensity projections (MIP) through a 300 µm-thick “slab” of the DECTacquired high-energy image volume, demonstrated the success of the rat hindlimb perfusions.
Epiphyseal nutrient arteries, and the associated foramen (red arrows) feeding the distal femoral
epiphysis (A) and proximal tibial epiphysis (B). Another source of blood vessels can be found
below the growth plate, as demonstrated in femur (C) and tibia (D), with red arrows denoting the
metaphyseal nutrient arteries and their associated foramens. Yellow arrows denote the primary
nutrient arteries (i.e. one major source of blood supply).
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Figure 4.4: Graph depicting the contrast enhancement of the femoral artery across the entire 8week long study. The mean femoral arterial values from 500 x 500 x 500 µm ROIs were collected
from both hindlimbs of all perfused rats. A paired t-test revealed no statistical differences (p =
0.9275) between ipsilateral and contralateral hindlimbs. Mean values, from both hindlimbs, at
each time point (T = 0 (pre-operatively), 1, 2, 4, and 8 weeks post-operatively) were averaged and
plotted with their standard deviation. Linear regression analysis reported across the entire study
duration revealed no statistically deviation from a slope of zero (p = 0.0828).

With the consistent and uniform perfusion across all rats, we acquired DECT scans of
both ipsilateral (operated) and contralateral (non-operated) hindlimbs from all rats, and
decomposed the acquired low- and high-energy volumes (Figure 4.5, top panels) into
their respective soft tissue, bone, and vessel volumes (Figure 4.5, bottom panels). To
visually emphasize the consistent success of our perfusion and DECT technique, we have
also presented radiographic projections through decomposed bone-, vessel-only, and a
composite image from selected samples of each surgery group and time-point
(Figure 4.6).
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Figure 4.5: Maximum intensity projections (MIP) through a perfused rat hindlimb that has been
DECT-scanned. Top panels display the DECT-acquired low- and high-energy volumes. The
automated DECT decomposition results in visually distinct bone and vessel-only images (bottom
panels).

94

Figure 4.6: A representative figure displaying the consistent and uniform perfusion of every
sample, regardless of surgery and time-point. Presented are x-ray projections through the bone(white), vessel-only (red), and a composite overlay of the decomposed volumes of a sample from
the sham or ACLX + PMM surgery group and at every time-point.
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Following the successful perfusion and DECT-decomposition of all rats, five selected rats
were DECT-scanned at a higher resolution (33 µm) to evaluate the effects of PVE. The
results of a repeated-measures, nonparametric, one-way ANOVA, and Dunn’s post-hoc
multi-comparative analysis on the measured microvessel voxel volume fractions from the
distal femoral epiphysis and proximal tibial epiphysis are displayed in Figure 4.7. The
statistical analysis revealed significant differences (p<0.05) between voxel volume
fractions recorded from volumes reconstructed at 33 and 132 µm, in both the femur and
tibia. Thus, it is apparent from our results that DECT is affected by PVE between the
extremes of the experimented rebinned voxel spacing range (i.e. 33 and 132 µm).
However, as an assurance, all samples within this study were scanned with identical scan
parameters, and identically decomposed and analyzed; thus, the results are directly
comparable with one another and should not be affected by PVE.

Figure 4.7: Graphs depicting the results of partial volume effects (PVE) on dual-energy microCT (DECT). Graphs displays the femur and tibia mean values and standard deviations of voxel
volume fractions collected from ROIs (i.e. distal femoral epiphysis and proximal tibial epiphysis)
within five perfused rats across natively-collected 33 µm and rebinned 2 × 2, 3 × 3, and 4 × 4 to
provide effective voxel spacings of 66, 99, and 132 µm, respectively. Repeated-measures,
nonparametric, one-way ANOVA, with Dunn’s post-hoc multi-comparative analysis, revealed a
statistical difference (p<0.05) between voxel volume fractions recorded at 33 and 132 µm in both
the femur and tibia.
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From each high-energy acquisition, operator-generated VOIs (Figure 4.1) of the distal
femoral epiphysis and proximal tibial epiphysis were transposed within each of their
respective inherently co-registered decomposed volumes (i.e. soft tissue, bone, and
microvessel) for both ipsilateral and contralateral hindlimbs. The average mean value was
collected from each individual VOI and arranged by decomposed component, anatomical
location, hindlimb and surgery group and plotted against time (i.e. T = 0 (preoperatively), 2, 4, and 8-weeks post-operatively). Presented are the results for the
microvessels (Figure 4.8), subchondral bone (Figure 4.9), and soft tissue (Figure 4.10).
Results of a two-way ANOVA analysis on the microvessel voxel volume fractions from
the ipsilateral (operated) and contralateral (non-operated) hindlimbs of the ACLX +
PMM surgery group revealed a statistical increase in the ipsilateral tibia 1 – week postoperatively (p = 0.0472, Figure 4.8). No further significant differences (p > 0.05) were
revealed between hindlimbs at the remaining time-points; at 2 – weeks post-operatively
and for the remainder of the experimental duration, the microvessel density returned and
remained at baseline levels (i.e. 0 – weeks, pre-operatively) (Figure 4.8). Thus, our
results suggest that angiogenesis within the ipsilateral tibia may be a result of an acute
inflammatory response immediately following surgery.
Analysis of subchondral bone voxel volume fractions (Figure 4.9), of the chosen ROIs,
between the ipsilateral and contralateral hindlimb of the ACLX + PMM surgery group
revealed no statistical differences (p > 0.05, two-way ANOVA, Prism) for each
individual time point. Thus, it appears that the combination of ACLX + PMM may not
significantly impact subchondral bone voxel volume fractions within our chosen ROIs of
the distal femoral epiphysis and proximal tibial epiphysis. This was surprising, as
previous research by our group using the same ACLX + PMM model has reported
volumetric bone mineral density (vBMD) changes between the ipsilateral and
contralateral hindlimbs.38 In the current study, the absence of detectable significant
changes in subchondral bone may be due to differences in ROIs used between the studies.
McErlain et al., utilized cylindrical ROIs with a 0.75 mm diameter and depth of ~ 1 mm
in the subchondral bone. Conversely, in our study we included some of the cortical shell
outlining the distal femoral epiphysis and proximal tibial epiphysis, in an effort to record

97

vessels that are known to penetrate the cortical shell and invade cartilage. Consequently,
the dense cortical shell may mask subtle changes to the subchondral bone densities and
provide overestimated voxel volume fractions of subchondral bone for our studied ROIs
(i.e. distal femoral epiphysis and proximal tibial epiphysis).

Figure 4.8: Results of the vessel voxel volumes fractions within custom 3D VOIs (Figure 4.1) of
the ipsilateral (operated) and contralateral (non-operated) hindlimbs’ distal femoral epiphysis and
proximal tibial epiphysis from both sham and ACLX rats over the 8-week study period. Each bar
represents the mean and standard deviation of N=6 rats per time-point.
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Figure 4.9: Results of the bone voxel volumes fractions within custom 3D VOIs (Figure 4.1) of
the ipsilateral (operated) and contralateral (non-operated) hindlimbs’ distal femoral epiphysis and
proximal tibial epiphysis from both sham and ACLX rats over the 8-week study period. Each bar
represents the mean and standard deviation of N=6 rats per time-point.
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Figure 4.10: Results of the soft-tissue voxel volumes fractions within custom 3D VOIs
(Figure 4.1) of the ipsilateral (operated) and contralateral (non-operated) hindlimbs’ distal
femoral epiphysis and proximal tibial epiphysis from both sham and ACLX rats over the 8-week
study period. Each bar represents the mean and standard deviation of N=6 rats per time-point.

To validate the sham surgery as an external control, we also performed a two-way
ANOVA statistical analysis on the voxel volumes fractions of microvessels (Figure 4.8),
bone (Figure 4.9), and soft tissue (Figure 4.10) obtained from ROIs within both the
ipsilateral and contralateral hindlimbs. For any of the decomposed components, our
results revealed no significant differences (p > 0.05) between the ipsilateral (operated)
and contralateral hindlimbs (non-operated) of the sham surgery group within each
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individual timepoint. Therefore, the sham surgery served as an effective external control
in this study.
As an additional comparison, using data collected from the ACLX + PMM surgery
group, we compared the microvessel voxel volume fractions of the distal femoral
epiphysis and proximal tibial epiphysis of both ipsilateral and contralateral hindlimbs
against the sham control. Analysis from a two-way ANOVA revealed no statistical
differences (p > 0.05) when comparing the ipsilateral or contralateral femurs and tibias
between both surgery groups (Figure 4.11). Of interest is the lack of significance between
the 1 – week ipsilateral tibias, as a significant increase was shown when comparing the
ipsilateral and contralateral hindlimbs of the ACLX + PMM surgery group (Figure 4.8).
This non-significance against the sham ipsilateral tibia may suggest that in the ACLX +
PMM group the release of inflammatory molecules post-surgery may be systemic,
causing an increase of angiogenesis in the ipsilateral hindlimb and a decrease within the
respective contralateral hindlimb. These results are not surprising, as previous research
has shown the increase in genetic expression,47,48 and inflammatory factors postsurgery.49-51
In contrast to simple greyscale thresholds on single-energy scans, we have shown that the
ability to mathematically decompose DECT-acquired volumes into individually
segmented and quantitative components, is resistant to PVE. To our knowledge, this
allowed our study to be the first to accurately quantify the microvessel density within the
distal femoral epiphysis and proximal tibial epiphysis of intact rat knee joints. The
average microvessel density of rats perfused at 0 – week (i.e. pre-operatively) in the distal
femoral epiphysis and proximal tibial epiphysis were 7.7 ± 1.5% and 7.2 ±1.3%,
respectively (Figure 4.8).
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Figure 4.11: Results of a comparison between microvessel voxel volumes fractions of the
ipsilateral (operated) and contralateral (non-operated) hindlimb between sham and ACLX +
PMM surgery groups. Each bar represents the mean and standard deviation of N=6 rats per timepoint.

Finally, histological sectioning and Toluidine blue staining confirmed the progression of
OA. Degeneration of the articular cartilage, as noted by a reduction in blue staining
(i.e. reduced proteoglycan and glycosaminoglycan concentration) was clearly present in
both the femur and tibia (Figure 4.12B, D, and F) of a hindlimb that underwent the
ACLX + PMM surgery. Conversely, a sample histological section taken from a 1 – week
post-operative sham operation revealed healthy cartilage (Figure 4.12A, C and E).
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Figure 4.12: Microscopic histological staining (Toluidine Blue) results of rat hindlimbs that have
undergone either a sham and ACLX + PMM surgery, 1 - week (A, C, and E) and 2-week (B, D,
and F) post-operatively, respectively. 10x magnification of the medial aspect of the joint,
displaying the intact (sham, A) or degenerated (ACLX + PMM, B) cartilaginous surfaces of the
femur (top) and tibia (bottom) of rats. 40x magnification of outlined regions-of-interest (ROI)
within the femur of sham (C) and ACLX + PMM (D) rats. 40x magnification of outlined ROIs
within the tibia of sham (E) and ACLX + PMM (F) rats. Note the loss of consistent Toluidine
Blue staining throughout the entire cartilage layer in (D) and (F), as well as a reduction in
chondrocyte organization, both indicative of cartilage degeneration.
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4.3.1

Limitations

The main limitation of our study lies in fact that the Er-based vascular perfusion contrast
agent is strictly limited for use with post-mortem samples.36 This limitation inhibits the
study of changes within the same vascular- and bone-networks within an animal, for
extended periods of time (i.e. longitudinal studies). However, current developments into
an in vivo vascular contrast agent,52 and corresponding optimized DECT protocols, can
overcome this challenge and is the topic of future studies within our group.
While the results of our statistical analysis of partial volume effects (PVE) on DECT
revealed a significant difference (p<0.05) between voxel volume fractions recorded from
a 33 µm and 132 µm reconstructed volume, a general downward trend can be observed in
Figure 4.7. Thus, it may be possible that results derived from our data (which was
reconstructed with 100 µm voxel spacing) may slightly underestimate the true
microvessel volume fractions. Acquiring DECT scans at 33 µm would provide a more
accurate representation of the vessel density (Figure 4.4); however, the time required to
scan all 100+ samples within this study would be significantly increased (i.e. 16 hr DECT
scan at 33 µm in comparison to 3 hr DECT scan at 100 µm per sample).
An additional limitation is the lack of an OARSI score within the rat hindlimbs. The
osteoarthritis research society international (OARSI) score is a standardized measurement
of OA severity within a rat joint. In this study, a small subset of rat joints was processed
for histological evaluation due to the large amount of time required to prepare all 108
samples for decalcification, histological sectioning, staining, and OARSI grading.
However, the surgical model of OA used in this study that has been previously wellcharacterized,38,39 and additional histological analysis can be carried out on the remaining
decalcified specimens.
In this study, the VOIs were limited to the distal femoral epiphysis and proximal tibial
epiphysis, due to their proximity to articular cartilage, known importance in nutrient and
oxygen supply to cartilage, and well-defined contours. However, the synovium53-55 and
patellofemoral region56-58 are also known to be required for the healthy maintenance of
the joint.53-55 As DECT-decomposition of the synovial membrane and patellofemoral
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regions were simultaneously acquired with the data presented in this study, research into
the associated bone and microvessel changes within these regions is a topic of further
research.

4.4 Conclusion
In an ACLX + PMM surgical model of OA, 8-week post-operative study period, and
chosen ROIs directly underlying the articular cartilage of the knee joint (i.e. distal
femoral epiphysis and proximal tibial epiphysis), we did not observe any significant
overall changes to the microvessel voxel volume fraction, suggesting that the subchondral
microvasculature did not play a significant role in our study of OA. Thus, future studies
using the same OA model and timeline as proposed in this study may benefit by
examining the microvessel changes within the neighbouring vascularized synovial
membrane and patellofemoral region.
Overall, in this study, we utilized a previously characterized combination technique – a
highly attenuating x-ray contrast agent36 with compatible, optimized DECT37 – to nondestructively, automatically and objectively segment individual quantitative volumes of
soft tissue, subchondral bone, and microvessels within a surgically-induced rat hindlimb
model of OA. While the current implementation of this combination imaging technique
cannot facilitate the visualization and resolution of individual microvessels (i.e.
capillaries, < 10µm), it provided quantitative measurements of tissue volume from 1 nL
voxels (i.e. 100 µm cubic voxels). This high degree of sensitivity allowed us to detect an
inflammatory or dilatory response 1-week post-ACLX + PMM surgery within the tibias
of operated hindlimbs, represented as a significant increase (p=0.0472) in microvessel
voxel volume fraction
The combination technique (i.e. contrast agent and optimized DECT) utilized within this
study provided the first-of-its kind ability to simultaneously study the soft tissue, bone,
and perfused vessels within an intact sample. However, the imaging and analysis
methodologies presented in this study are not limited to OA, but can be advantageous for
the examination of interactions between different tissues in vascular-related diseases:
neurological,59 cardiovascular,60,61 musculoskeletal,60,62,63 and oncological.64-66
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Chapter 5

5

Conclusion and Future Directions

5.1 Summary of Results
Osteoarthritis (OA) affects ~10% of Canadians over the age of 15,1 making it a disease
no longer just a concern among the aging population. Currently, there are no therapeutic
treatments or disease modifying osteoarthritic drugs (DMOADs) that can halt and reverse
the bone and cartilage damage caused by OA.2,3 The absence of preventative and
reversing treatments is due to a lack in knowledge regarding the initiation and
progression of OA. Multiple confounding factors such as age,4,5 diabetes,6-8 obesity,4,6,9
and prior injuries10-12 are responsible for the complexity surrounding OA. Therefore,
research into OA is beneficial towards understanding the disease and revealing new
targets for drug development.
Recently, a re-emerging OA hypothesis revolves around subtle changes to the delicate
microvascular environment surrounding joints.13,14 Due to the avascular (i.e. lack of
vessels) nature of cartilage, it is known that their nutrient and oxygen must be supplied
from the highly-vascularized neighbouring synovium and subchondral bone.15 Therefore,
slight variations (i.e. a decrease or increase) in the homeostatic vascular density of these
critical structures (i.e. synovium and subchondral bone) may negatively impact and
promote their degeneration and the degeneration of cartilage.16 Nutrients and oxygen
from the synovium are known to play an important role in the maintenance of cartilage;
however, there is a lack of research in understanding the role of subchondral bone
microvessels, more specifically, the distal femoral epiphysis and proximal tibial epiphysis
as they neighbor cartilage.
Unfortunately, the small size of microvessels (i.e. 5 – 10 µm for capillaries), lack of
contrast against surrounding tissues, and proximity to dense bony structures, have
hindered their segmentation, characterization, and quantification. Pre-clinical micro-CT
is already widely available and routinely used for the visualization and characterization of
dense objects, such as bone;17,18 in combination with an exogenous vascular contrast
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agent,19,20 simultaneous visualization of bone and vessels can be achieved. However,
commercially contrast agents provide bone-like greyscale values – hindering their
automatic segmentation from one another.21 Thus, we created a custom ex vivo vascular
perfusion contrast agent that provides significantly higher contrast than commercially
available agents, and is compatible with dual-energy micro-computed tomography
(DECT). The advantageous use of DECT allows us to automatically decompose DECTacquired volumes into separate and quantifiable 3D volumes of soft tissue, subchondral
bone, and vessels.
With a highly x-ray attenuating contrast agent and optimized DECT, we combined them
with a well-characterized surgically induced rat hindlimb model of OA.22,23 The
combination of an anterior cruciate ligament transection (ACLX) and partial medial
meniscectomy (PMM) has been shown to mimic the subtle subchondral bone changes
exhibited in early-onset OA within humans, making it ideally suited for the study of
microvessel changes. The combination of a custom vascular contrast agent and DECT
with a surgically-induced rat hindlimb model of OA (i.e. ACLX + PMM) and
observational period of 8 – weeks post-surgery, facilitated the simultaneous study of
subchondral bone and microvessel density changes during the initiation and progression
of OA.
In Chapter 2, titled “Erbium-Based Perfusion Contrast Agent for Small Animal
Microvessel Imaging”, a methodology was described to facilitate the fabrication of a
custom ex vivo vascular perfusion contrast agent comprised of homogeneously
incorporated erbium oxide (Er2O3) nanoparticles within a two-part silicone elastomer
carrier media. Erbium, a lanthanide, was chosen as the base of the contrast agent due to
its high x-ray absorption and optimally placed absorption K-edge energy (57.5 keV) for
DECT. To break up naturally large aggregates of Er2O3, ultrasonic cavitations was
employed to facilitate the suspension of nano-sized Er2O3 aggregates within the prepared
media. Particle sizes were confirmed with transmission electron microscopy (TEM) and
dynamic light scattering (DLS, 64.8 ± 11.1 nm). A measured viscosity of 19.2 mPa∙s
ensured the perfusion of the prepared suspension into microvessels (i.e < 10 µm). To
demonstrate the efficacy of the custom contrast agent, whole intact mice were perfused
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and subsequently scanned with micro-CT. The results of multiple scanned mice revealed
perfused vasculature with significantly higher contrast (> 4000 HU) in comparison to
surrounding skeletal structures (2359 ± 207 HU) and a commercially available lead-based
contrast agent (MV-122, 2683 ± 77.6 HU). The significantly enhanced contrast allowed
for the easier visualization of vessels running through foramens (i.e. passages that allow
vessels to enter bone), and within long bones (i.e. femur and tibia). Micro-CT scans of a
perfused mouse kidney at a higher resolution (i.e. ~ 5 µm) revealed perfused glomeruli
(i.e. capillary beds) and afferent arterioles (~ 13 µm), validating the ability of the custom
Er-based contrast agent to perfuse microvessels.
Dual-energy micro-CT facilitates the automatic segmentation of materials-of-interest
based on the change in their x-ray attenuation coefficient between two x-ray energies.
The ability to differentiate components can be further enhanced by shifting the CT
scanners’ mean energy above and below the absorption K-edge of the material of interest.
However, the lack of preferential x-ray filtration on pre-clinical cone-beam laboratorybased micro-CT scanners results in poor spectral separation. The addition of metal foils,
acting as x-ray filters, can vastly improve spectral separation; yet, this requires opening
and modifying the gantry. To avoid machine modifications, in Chapter 3, entitled “DualEnergy Computed Tomography for a Gantry-Based Pre-Clinical Cone-Beam Micro-CT
Scanner”, we developed techniques to fabricate customizable in-bore x-ray filters,
automate DECT-acquisition, image co-registration, and decomposition algorithms for
conventional pre-clinical cone-beam micro-CT scanners. As previously outlined in
Chapter 2, Er has an absorption K-edge energy (57.5 keV) located near the mean x-ray
energy of micro-CT scanners (~42.7 keV) that operate at maximum x-ray tube potential
of 90 kVp. Using Er2O3 nano-powder and simple silicone molding techniques, we
successfully fabricated a custom cylindrical annular low-energy Er-embedded resin x-ray
filter. A removable cylindrical annular-shaped filter would negate the need of modifying
the scanner, and would provide x-ray filtration irrespective to gantry rotation. Combined
with an identically shaped high-energy Cu filter, these x-ray filters would provide the
necessary spectral separation for DECT. We mounted the x-ray filters on a custom
automated filter-exchange mechanism that automatically switches x-ray filters within the
scanner bore in between low- and high-energy scans. To correct for inherent gantry
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motions and non-reproducible bed movements, fiducial marker beads embedded within
the sample holder aided in the sub-voxel co-registration between the low- and highenergy volumes. The combination of all the previously outlined developments resulted in
the successful implementation of optimized DECT for an Er-based contrast agent on a
pre-clinical cone-beam micro-CT scanner. The success of the DECT setup was
demonstrated via the highly accurate automatic decomposition of Er-perfused rat
hindlimbs into separate, distinct, and quantifiable 3D volumes of soft tissue, bone, and
perfused vasculature. Statistical analysis of measurements from known pure areas
(100 µm3) of soft tissue, bone, and perfused vessels within each decomposed volume
revealed decomposition accuracies of > 98.5%.
In Chapter 4, titled “Studying femoral- and tibial-subchondral bone and vascular changes
using dual-energy micro-computed tomography in a surgically-induced rat hindlimb
model of osteoarthritis”, the combination of an Er-based vascular perfusion contrast agent
(Chapter 2) and optimized DECT (Chapter 3) were utilized for the simultaneous
investigation into subchondral bone and microvessel density changes during the initiation
and progression of OA. For this study we used rats that were divided into various time
points (i.e. T = 0, 1, 2, 4, and 8 weeks post-operatively) and OA-surgery was performed
solely on the right hindlimb. As a control, we utilized both a sham surgery and the
contralateral (non-operated) hindlimb from each rat. Due to the avascular nature of
cartilage (i.e. absence of blood vessels), we chose to study the microvessel network of the
neighbouring distal femoral epiphysis and proximal tibial epiphysis. Due to the proximity
of the chosen ROIs to cartilage, the microvessels within the ROIs may be responsible for
delivering nutrients and oxygen to cartilage. Statistical analysis of microvessel volume
fractions revealed a significant increase (p = 0.0472) in microvessel density within the
ipsilateral tibia 1 – week post-operatively, in comparison to the contralateral hindlimb.
This change in vessel density is most likely due to an acute inflammatory response and
subsequent angiogenesis. 2 – weeks post-operatively, and till the end of the experiment,
the microvessel density returned to baseline (i.e. 0 – week).

With regards to the

subchondral bone and soft tissue, the inflammatory response did not significantly affect
these tissues within the chosen ROIs for the entire duration of the study.
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5.2 Future Directions
The accumulation of results from the chapters presented within this thesis have
demonstrated our ability to (1) produce customized elemental composition vascular
contrast agent; (2) fabricate customized shape and composition x-ray filtration for
element specific DECT; and (3) combine the previously mentioned techniques to
simultaneously study subchondral bone and perfused microvessels within a rat hindlimb
model of OA. While our accomplishments have been applied in the study of OA, the
advancements achieved within each Chapter can be beneficially adapted for a wide range
of applications and studies.

5.2.1

Customized Contrast Agents

We have demonstrated the capabilities of using Er as the basis of a vascular perfusion
contrast agent (Chapter 2). An Er-based agent provides significantly higher x-ray contrast
than commercially available contrast agents, and its absorption K-edge energy is
optimally located for its use with DECT. Recent research, has adapted the base of our Erbased contrast agent for in vivo experiments,24 facilitating the study of the same
microvessel networks over time in response to various external challenges (i.e. induction
of vascular-related diseases, angiogenic, anti-angiogenic drugs, etc). In addition to
demonstrating the effectiveness of an Er-based contrast agent, the techniques
implemented for the fabrication of our contrast agent can be applied to customizing a
wide variety of contrast agents.
Un-coated or un-treated nanopowders will tend to clump together due to van der Waals
forces.25,26 However, in Chapter 2, we have shown that ultrasonic cavitation is effective
in breaking down larger aggregates of nanoparticulate Er2O3 into nano-sized
aggregates.27 Thus, the application of ultrasonic cavitations for the incorporation of
nanoparticles within a media can lead to the fabrication of vascular contrast agents of
customizable elemental compositions, concentrations, and carrier media.
The ability to customize the vascular contrast agent may lead to the development of more
multimodal imaging contrast agents.28 With respect to micro-CT, as high-energy (i.e.
>120 kVp) x-ray scanners become more available, contrast agents of higher-Z elements
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(i.e. higher electron density) would be more favourable29 for greater contrast (i.e.
increased x-ray attenuation) within images. Furthermore, vascular contrast agents
exhibiting higher-energy absorption K-edge energies can be advantageous for DECT, as
the increased photon flux above and below the K-edge will require shorter scan times,
and subsequently reduced x-ray dose.

5.2.2

Customizable DECT

The ability to customize the vascular perfusion contrast agent (Chapter 2) combined with
our results from Chapter 3 (i.e. the fabrication of a large variety of custom sized, shape,
and composition x-ray filters) opens the door for DECT to be customized for specific
elements-of-interest. We provided the basic technique for the creation of a custom Erbased x-ray filter using inexpensive materials and simple molding techniques. This
process allows other researchers to craft custom shaped molds (i.e. cylindrical,30 wedge,31
or bowtie filters32,33) to cast x-ray filters impregnated any element available in nanopowder form – tailoring the output x-ray spectra of the micro-CT scanner to optimize
contrast and DECT performance for any material-of-interest.
In Chapter 3 we also presented a custom filter-exchanger that fit within the bore of the
micro-CT scanner and allowed for the automated acquisition of DECT images –
preventing the need to open and modify the x-ray scanner. Additionally, an automated
co-registration software utilized fiducial marker beads surrounding the sample to provide
sub-voxel co-registered DECT-acquired volumes. This method of co-registration allowed
for the correction in inherent gantry motions and non-reproducible bed movements.
Together, we provided an effective implementation of DECT on a large installed base of
pre-clinical cone-beam micro-CT scanners.

5.2.3

Vascular Disease Research

In the previous Chapters, we have demonstrated the effectiveness of the combination of
our Er-based contrast agent (Chapter 2) and automated DECT technique (Chapter 3) in
facilitating the distinct segmentation, visualization, and highly specific quantification of
the individual decomposed volumes of soft tissue, bone, and perfused vessels. The results
from Chapter 2 and 3 facilitated the simultaneous visualization and quantification of
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subchondral bone and microvessels in the distal femoral epiphysis and proximal tibial
epiphysis of rats that have undergone an OA-induced surgery. Our results showed an
acute inflammatory response 1 – week post-operatively that resulted in a significant
increase (p = 0.0472) of microvessel density within the ipsilateral tibia, compared to the
contralateral (non-operated) hindlimb. However, 2 – weeks post-operatively the
microvessel density returned to and remained at baseline levels (i.e. 0 – week) for the
remainder of the experimental timeframe. Thus, our results suggest that the microvessel
density changes within the studied ROIs (i.e. distal femoral epiphysis and proximal tibial
epiphysis) may not indicate substantial changes with the current OA model (i.e. ACLX +
PMM). As mentioned in the discussion of limitations in Chapter 4, there is growing
interest in the role of the synovial membrane with respect to the supply of oxygen and
nutrients to articular cartilage. Some recent papers suggest that the majority of nutrients
to cartilage is provided from the synovium.34-36 In this case, it would be of potential
interest to apply our new DECT analytic technique to study concurrent changes in the
vasculature of the synovium. In the present study, the synovium of rats was not analyzed,
mainly due to the difficulty in defining a consistent 3D volume of interest within this
complex structure. However, it is interesting to note that the data acquired in Chapter 4
includes quantitative information about the vascular density within the synovium; this
could be studied through retrospective analysis, using operator-defined synovial VOIs.
We have performed some preliminary work in this regard, and Figure 5.1 shows a
representative contour, 3D-generated VOI, and maximum-intensity projection through a
vessel-only DECT-decomposed volume. This preliminary data demonstrates the highly
vascularized synovial membrane, consistent with current theories about the role of the
synovium in cartilage health and disease. All of the raw 3D images for each rat in this
study have been digitally archived, facilitating a retrospective analysis of changes in
synovial vascular density as part of a future study.
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Figure 5.1: Results displaying the contouring process and resulting DECT-decomposed vessels
of the synovium from a representative Er-perfused rat hindlimb. (A) An operator-generated 2D
contour was iterated every 200 µm. (B) Interpolation of these 2D contours resulted in a 3D VOI.
(C) A thick slice maximum intensity projection (MIP), representing the contour in (A), through
the DECT-decomposed vessel-only volume displaying the highly vascularized synovium. (D) A
maximum intensity projection through the entire 3D VOI (anterior – posterior).
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Apart from our use of an Er-based contrast agent and DECT for the study of bone and
vessel changes within a model of OA, the characterization and quantification of bone and
vessels can be applicable to a large variety of vascular-related research: cardiac,37
musculoskeletal,38,39 oncogenic,40 and neurological.41 To emphasize this strength of our
novel technique, we sought out collaborations to study vascular changes within
oncogenic and musculoskeletal diseases.
Our first collaboration involved the investigation of tumour angiogenesis following
treatment with an anti-vascular endothelial growth factor (VEGF) and within control (i.e.
non-treated) tumours.42 The cancer cell line used within this study (i.e. MDA-MB-231D3H2-LNluc) can calcify and appear like bone within micro-CT scans. Our role in this
collaboration was to provide a technique that would facilitate the visualization of
microvessels even in the presence of tumour calcification. The application of our highly
x-ray attenuating Er-based contrast agent and optimized DECT will provide the ability to
distinguish between vessels permeating possible calcified regions of the tumour. The
results of the our micro-CT scans revealed the entire perfused vascular system of a mouse
(Figure 5.2A), the tumors encapsulating microvasculature (Figure 5.2B), and blood
supply within the tumour mass (Figure 5.2C).42
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Figure 5.2: Micro-CT results of a mouse and its associated tumour mass perfused with a custom
Er-based vascular perfusion contrast agent. (A) Maximum intensity projection (MIP)
demonstrating the perfusion of a whole mouse perfused with our Er-based contrast agent. (B) A
segmented control tumour mass with a simple threshold isosurface to display its vascular
encapsulation. (C) A segmented tumour mass treated with an anti-VEGF drug with a simple
threshold isosurface displaying the affected vascular encapsulation. Taken and modified from
Lowerison et al., 2017.42
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In addition to studying angiogenesis within a tumour, we also had the opportunity to
study the effects of vessel growth within the spine of genetically modified mice (CCN2deficient) that undergo accelerated age-related intervertebral disc degeneration (IVD)
(Bedore et al., submitted 2017 to Scientific Reports). Our role in the collaboration was to
examine the presence of vascular invasion into the IVDs of CCN2-deficient mice. Like
cartilage, IVDs are an avascular tissue requiring nutrients and oxygen through diffusion
from surrounding vascularized tissues. The proximity and known function of nearby
endplates to provide nutrient and oxygen43 necessitated the need of our Er-based contrast
agent and DECT to ensure the visualization of perfused vessels. However, in this case
DECT was not required as vascular invasion into the IVDs originated from the spinal
cord rather than the underlying bone (Figure 5.3).
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Figure 5.3: Representative thick-slice (300 µm) maximum intensity projections (MIP) of a
single-energy micro-CT scan displaying the (IVD) and adjacent spinal cord (SC). A control
(left) and CCN2-deficient (right) mouse were perfused with our Er-based vascular perfusion
contrast agent, vertebral body microvasculature and microvasculature adjacent to the IVD space
(red arrows). No overt differences in vascularity were observed within the IVD space between
both the control and CCN2-deficient mice, with microvasculature at the immediate periphery of
the IVD space and absence of vasculature within the IVD space. Modified from data submitted
as part of a manuscript (Bedore et al., 2017, Scientific Reports).
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5.3 Summary
In conclusion, this thesis has described the development and implementation of a new
type of endogenous vascular contrast agent for ex vivo use with small-animal models. The
contrast agent exhibits a number of advantageous properties, including the ability to
perfuse the smallest vessels, high-contrast relative to other tissues and bone, and x-ray
attenuation properties that are ideally suited to dual-energy CT on laboratory scanners.
This new technique has been used in a study of vascular changes in a rat model of
osteoarthritis, and has also been adopted quickly in collaborative studies of the
vasculature near tumours and within the spine. The combination of the erbium-based
contrast agent and dual-energy scanning facilitates the automated segmentation of vessels
from other tissue types (including bone), providing a potentially powerful tool for future
research involving the micro-vasculature of small-animal models.
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Appendix A
Additional Analysis for the Resuspension of a Two-Year Old
Er-Based Vascular Perfusion Contrast Agent

Figure A.1: DLS measurements of particle size distribution of a two-year old prepared Er-based
suspension that was sonicated for either 5 or 10 minutes prior to measurement.
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Appendix B
Animal Ethics Approval

2015-018::1:
AUP Number: 2015-018
AUP Title: TGFα/EGFR signaling in osteoarthritis
Yearly Renewal Date: 07/01/2016
The YEARLY RENEWAL to Animal Use Protocol (AUP) 2015-018 has been
approved, and will be approved for one year following the above review
date.

1. This AUP number must be indicated when ordering animals for this
project.
2. Animals for other projects may not be ordered under this AUP number.
3. Purchases of animals other than through this system must be cleared
through the ACVS office.
Health certificates will be required.
REQUIREMENTS/COMMENTS
Please ensure that individual(s) performing procedures on live animals, as described
in this protocol, are familiar with the contents of this document.
The holder of this Animal Use Protocol is responsible to ensure that all associated
safety components (biosafety, radiation safety, general laboratory safety) comply
with institutional safety standards and have received all necessary approvals. Please
consult directly with your institutional safety officers.
Submitted by: Kinchlea, Will D
on behalf of the Animal Use Subcommittee
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Appendix C
Dual-Energy Computed Tomography Decomposition
Algorithm Detailed Explanation
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The implementation of dual-energy computed tomography (DECT) decompositions
within this Ph.D. thesis has been previously outlined and described in greater detail by
Granton et al., 2008. However, briefly, the decomposition algorithm relies on the solution
of the following three equations:

eq. 1

µSoft Tissue(HighE)⨍Soft Tissue + µBone(HighE)⨍Bone + µVessel(HighE)⨍Vessel = µHighE

eq. 2

µSoft Tissue(LowE)⨍Soft Tissue + µBone(LowE)⨍Bone + µVessel(LowE)⨍Vessel = µLowE

eq. 3

⨍Soft Tissue +⨍Bone + ⨍Vessel = µHighE

From eq. 1 and eq. 2, the observed attenuation coefficient recorded within each individual
voxel in the acquired low- (µLowE) and high- (µHighE ) energy volumes is comprised of the
fractional contribution of three materials of interest (i.e. ⨍Soft Tissue , ⨍Bone , and ⨍Vessel) and
their respective attenuation coefficient at that acquired x-ray energy
(i.e. µSoft Tissue(Low/HighE). µBone(Low/HighE), and µVessel(Low/HighE)). In eq. 3 we assume that a voxel
can only be comprised of the fractional contribution from either soft tissue, bone, or
vessel and that the sum of their fractional contribution must equal 1 (i.e. 100%).
The µ values, within eq. 1 and eq. 2, for each tissue were acquired from the mean CT
value in Hounsfield units (HU) from 500 × 500 × 500 µm regions-of-interest (ROI), in
both low- and high-energy acquired volumes, from areas of pure soft tissue, bone, and
vessel. The mean CT value was used, as this value is linearly proportional to the tissue’s
respective attenuation coefficient. The initial six CT values (i.e. “seed values”) inputted
into eq. 1 and 2 are highly dependent on known areas of pure tissues. Using improper
seed values will result in non-ideal decompositions (i.e. misclassified voxels, Fig. 3.5 and
3.8), visualized as components bleeding into one another (Fig. 3.7 and 3.9). To optimize
the six seed values – resulting in a highly accurate decomposition – an iterative approach
was taken.
The initial six seed values were chosen by recording the mean value from 500 × 500 ×
500 µm ROIs within areas of known soft tissue (bicep femoris), bone (cortical bone), and
vessel (femoral artery). Unfortunately, as Er-perfused microvessels are located
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throughout the bicep femoris and cortical bone, the recorded CT values will be higher
than expected. The resulting automatically decomposed volumes will contain many
misclassified voxels. Thus, to further finetune the seed values and obtain more accurate
CT values for non-vascularized soft tissue and bone, a mask for each tissue was
generated for each decomposed volume. The separate “tissue masks” were obtained by
choosing a threshold value within each decomposed volume above the value of tissues
“bleeding” into that volume. A custom in-house Unix-based script would then provide a
mean value of all the voxels within each decomposed value that was above the threshold
value, providing a new seed value for said tissue component. This iterative approach was
performed a max number of ten times for each tissue at both low- and high-energy until
an ideal set of six seed values was obtained (Table 3.1), resulting in decomposed volumes
of solely soft tissue, bone, and vessel were obtained (Fig. 3.4). Therefore, all that remains
from eq. 1-3 are the voxel volume fractions of soft tissue, bone, and vessel (i.e. ⨍Soft Tissue
, ⨍Bone , and ⨍Vessel ).
To determine the voxel volume fractions of each tissue, we employed a matrix
factorization approach to solve a system of linear equations (i.e. eq. 1-3). The results of
these calculations (performed for each voxel within the acquired low- and high-energy
volumes), are individual volumes of the three materials-of-interest (i.e. soft tissue, bone,
and vessel). Within each decomposed volume, greyscale values (0 – 10,000) of individual
voxels represented the voxel volume fraction or percent contribution (0 – 100%) of said
component to that specific voxel. Thus, the decomposition algorithm resulted in three
tissue-distinct 3D volumes, where greyscale values represented the percent contribution
of a tissue on a voxel.
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